



Early View

State of the Art

Understanding the Pathophysiological Mechanisms of Cardiometabolic Complications in Obstructive Sleep Apnoea – Towards Personalised Treatment Approaches

Silke Ryan, Eoin P. Cummins, Ramon Farre, Alex Gileles-Hillel, Jonathan C. Jun, Henrik Oster, Jean-Louis Pepin, David W. Ray, Sirimon Reutrakul, Manuel Sanchez-de-la-Torre, Renaud Tamisier, Isaac Almendros

Please cite this article as: Ryan S, Cummins EP, Farre R, *et al.* Understanding the Pathophysiological Mechanisms of Cardiometabolic Complications in Obstructive Sleep Apnoea – Towards Personalised Treatment Approaches. *Eur Respir J* 2020; in press (<https://doi.org/10.1183/13993003.02295-2019>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Understanding the Pathophysiological Mechanisms of Cardiometabolic Complications in Obstructive Sleep Apnoea – Towards Personalized Treatment Approaches

Silke Ryan^{1,2}, Eoin P Cummins², Ramon Farre³, Alex Gileles-Hillel⁴, Jonathan C Jun⁵, Henrik Oster⁶, Jean-Louis Pepin⁷, David W Ray⁸, Sirimon Reutrakul⁹, Manuel Sanchez-de-la-Torre^{10,11}, Renaud Tamisier⁷ and Isaac Almendros³

Affiliations:

¹Pulmonary and Sleep Disorders Unit, St. Vincent's University Hospital, Dublin, Ireland

²School of Medicine, Conway Institute, University College Dublin, Ireland

³Unitat de Biofísica i Bioenginyeria, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona-IDIBAPS, and CIBER Enfermedades Respiratorias, Barcelona, Spain

⁴Pediatric Pulmonology and Sleep Unit, Department of Pediatrics, and The Wohl Institute for Translational Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

⁵Pulmonary and Critical Care Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA

⁶Institute of Neurobiology, University of Lübeck, Lübeck, Germany

⁷HP2 INSERM U1042, Université Grenoble Alpes, Grenoble, France

⁸NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK and Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK

⁹Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA

¹⁰Group of Precision Medicine in Chronic Diseases. Hospital Arnau de Vilanova-Santa Maria. IRBLleida. Lleida, Spain.

¹¹Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain

Corresponding author: Dr Silke Ryan
Dept. of Respiratory Medicine
St. Vincent's University Hospital,
Elm Park,
Dublin 4, IRELAND.
Tel: 353-1-221 3702
Fax: 353-1-221 3126
E-mail: silke.ryan@ucd.ie

Abstract

In January 2019, a European Respiratory Society (ERS) Research Seminar entitled “Targeting the detrimental effects of sleep disturbances and disorders” was held in Dublin, Ireland. It provided the opportunity to critically review the current evidence of pathophysiological responses of sleep disturbances, such as sleep deprivation, sleep fragmentation or circadian misalignment and of abnormalities in physiological gases such as oxygen and carbon dioxide which are frequently occurring in respiratory conditions during sleep. A specific emphasis of the seminar was placed on the evaluation of the current state of knowledge of the pathophysiology of cardiovascular and metabolic diseases in obstructive sleep apnoea (OSA). Identification of the detailed mechanisms of these processes is of major importance to the field and this seminar offered an ideal platform to exchange knowledge, to discuss pitfalls of current models and the design of future collaborative studies. We also debated the limitations of current treatment strategies for cardiometabolic complications in OSA and discussed potentially valuable alternative approaches.

Keywords: obstructive sleep apnoea, intermittent hypoxia, hypercapnia, sleep disturbances, circadian misalignment

Obstructive sleep apnoea (OSA) is a highly prevalent disorder which has rapidly evolved into a major global public health burden [1, 2]. It is independently linked with the development and control of numerous cardiovascular and metabolic conditions including hypertension, coronary artery disease, stroke, heart failure, type 2 diabetes (T2D) or non-alcoholic fatty liver disease (NAFLD) leading to substantial morbidity and mortality [1, 3-5].

Despite significant efforts being made, the pathophysiological mechanisms underlying cardiometabolic disease processes in OSA remain incompletely understood. OSA is a complex disorder and clinical studies have often been limited by the coexistence of frequent comorbid conditions, heterogeneity in clinical presentation and large variability in duration of the disease prior to diagnosis. Thus, much of our knowledge of the pathogenesis has been conducted by translational studies using experimental models. The hallmark features of OSA, namely intermittent hypoxia (IH) and sleep fragmentation (SF), have been identified as key players in cardiometabolic processes in OSA [6]. However, the interaction between these two pathophysiological triggers and moreover, the relative contribution of other potential traits are poorly defined.

Over the last few years, the detrimental effects of sleep disturbances in general on morbidity and mortality have been increasingly recognized and important pathophysiological roles have been attributed not only to SF but also to sleep deprivation or circadian misalignment. However, these factors remain inadequately explored in OSA. Furthermore, recent evidence supports important immune and inflammatory modulation in response to hypercapnia [7] and although it is a well-recognized feature in OSA, it has gained little attention as a potential contributor to adverse consequences.

Unravelling the detailed mechanisms underlying cardiovascular and metabolic disease processes in OSA is of major importance and will likely lead to the identification of novel treatment strategies. Continuous positive airway pressure (CPAP) therapy is the treatment of

choice in OSA, but its benefits on cardiometabolic health remain uncertain. In order to advance this important field, the European Respiratory Society (ERS) Research Seminar entitled “Targeting the detrimental effects of sleep disturbances and disorders”, held in Dublin in January 2019, brought together international experts and research groups from different areas of sleep medicine to promote exchange of knowledge, to identify specific research questions and to facilitate future collaborative projects. This perspective summarises the key learning points, conclusions and proposals from the seminar.

Intermittent Hypoxia – past, present and future

Experimental models of intermittent hypoxia – benefits and limitations

Intermittent hypoxia (IH) plays a key role in the pathophysiology of cardiometabolic disease processes in OSA and in support, various clinical studies have identified the superiority of markers defining the severity of IH in the prediction of cardiovascular outcomes over the traditional apnoea/hypopnoea index (AHI) which predominantly reflects airflow limitations [8-10]. Recent studies recognized the hypoxic burden, a single marker capturing the frequency, duration and depth of obstructive events-associated oxygen desaturation, as potentially valuable metric in this setting, however, its superiority over other traditional polysomnographic IH-related parameters such as the oxygen desaturation index (ODI) will require further longitudinal studies [11, 12]. Detailed insight into the effects of IH has been predominantly provided by studies using experimental models. The non-invasive rodent model of IH where the animals alternately breathe nitrogen-enriched air to simulate hypoxia and air or oxygen for the reoxygenation phase has been fundamental to the field and there have been excellent reviews summarizing the contribution of this model to our current knowledge [13-15]. However, the model has also considerable limitations and hence, results of those animal studies cannot automatically be extrapolated to the human condition of OSA.

Firstly, the rodent model does not accurately reflect the oxygenation pattern seen in OSA patients with the latter being characterized by a considerable intra-and inter-subject variability and generally less severe desaturations than that of the rodent model [16]. Secondly, rodent's sleep is not as consolidated as that of humans and hence, a significant proportion of the IH occurs while the animal is awake. Although systems have been developed to trigger the IH during sleep only [17, 18], given the labour- and cost-intensive nature of this approach, most models use IH unlinked to sleep. Thirdly, an increasing body of evidence supports the potentially very significant confounding effects of external stressors such as cold temperature, diet or housing conditions on inflammatory and immune responses in rodents [19]. Furthermore, as mentioned above, the IH model does not recapitulate all the effects of OSA and new approaches to non-invasively reproduce upper airway obstruction may be more suited to study detrimental effects in OSA [20, 21].

Cell culture models of IH have been utilized to complement animal studies and have allowed the investigations of detailed IH-induced cellular responses and signalling mechanisms in different cell lines [22-25]. These models have continuously advanced over the last years. Growing cells on ultrathin, semi-permeable membranes allows rapid oscillations in the partial pressure of oxygen and fully automated systems facilitate the application of an adequate control exposure in parallel to the IH treatment with tight control of potentially confounding parameters such as temperature or carbon dioxide tension [24]. Thus, many limitations associated with earlier approaches have been overcome and cell culture studies are likely to grow in their importance to the field. However, the specific IH patterns at the cellular level in relevant tissues in humans with OSA remain largely unknown and therefore, may not be accurately reflected in *in vitro* studies which remains a significant limitation.

In order to bridge the gap between animal models and clinical studies, human models exposing healthy volunteers to IH have been developed and have provided substantial additional insight into the acute effects of IH [26]. Experiments have shown that several weeks of IH for 8 hours each night lead to blood pressure elevation and a sustained increase in sympathetic tone [27]. These changes are coupled with an alteration in arterial baroreflex sensitivity and an increase in hypoxic chemosensitivity illustrating the impact of IH exposure on autonomic activity which is one of the key mechanisms of neurogenic hypertension exhibited by OSA patients [27, 28]. So far, the usage of such models is limited due to the substantial costs and ethical considerations. Furthermore, they are similarly limited to IH and sleep fragmentation, but do not include other pathophysiological traits of OSA such as hypercapnia or respiratory efforts. Combining such factors and exposing not only healthy humans but patients without OSA in the future might provide us with invaluable benefit understanding the very detailed mechanisms of cardiometabolic diseases in OSA.

Adaptive and maladaptive responses to IH: where is the threshold?

Depending on the frequency of cycles, the depth of the hypoxic period and the duration of the exposure, IH can induce both, beneficial and detrimental effects, and hence, is considered as a “double-edged sword”. Short exposures to low-frequency IH with mild hypoxia improves endurance performance of athletes, facilitates high-altitude acclimatization and may be cardio- and neuroprotective through pre- and postconditioning effects [29-35]. Furthermore, recent studies suggested that exposure to mild IH initiates long-term facilitation of upper airway muscle activity and thus, may be a therapeutic modality to reduce treatment pressure of CPAP in OSA patients [36]. In contrast to these effects of mild IH, the chronic IH pattern typically associated with moderate or severe OSA is associated with numerous deleterious consequences [37, 38]. Furthermore, as suggested by various animal studies, the duration of IH exposure may determine the potential reversibility of its consequences [39, 40]. Hence, a

key question in the field relates to the determination of the actual threshold between these opposite effects. It is increasingly recognized that this threshold can be modified by various factors. Particularly, the impact of age has gained increasing attention stimulated by clinical observations suggesting blunted cardiovascular outcomes in elderly OSA subjects [41-43]. Intriguingly, programmed cell death- 1 (PD- 1) receptor and its ligand (PD- L1) are upregulated in OSA subjects in comparison to healthy controls which, however, is not evident in older patients attributed to an impaired activation of HIF-1 α and this differing response may account at least in part for the increased cancer mortality seen in younger OSA subjects [44]. Recent animal studies lend support for this hypothesis demonstrating a blunting of vascular remodelling in older in comparison to younger mice [45]. Other factors which may contribute to the shift from an adaptative to a mal-adaptative response in OSA include genetic susceptibility, gender, age, smoking habits, physical activity and the presence of comorbidities such as obesity, established cardiovascular disease, diabetes or others [37] (Figure 1). It will be essential to study these modifying factors and their interactions with IH in future pre-clinical experiments in greater detail and these results may assist predicting the consequences of OSA and the potential benefits of its treatment for specific patient phenotypes.

Novel insights into the detrimental cardiometabolic effects of IH

Despite limitations of the current models of IH there is continuously growing evidence of the detrimental effects of this hallmark feature in cardiometabolic disease processes in OSA. Table 1 highlights important findings of recent publications (Table 1). Clinical and experimental studies have shed further insight into the mechanistic pathways of IH-mediated hypertension. Although previous studies failed to demonstrate benefit of supplemental oxygen on blood pressure [46, 47], in a recent randomized controlled trial in patients with moderate to severe OSA, supplemental oxygen delivered at a high-flow rate but

not sham treatment abolished morning blood pressure rise following CPAP withdrawal for 2 weeks supporting the key role of IH in this process [48]. Furthermore, this response was associated with upregulation of genes of the nuclear factor (NF)- κ B-associated proinflammatory pathway in circulating leucocytes providing further evidence of the pivotal contribution of inflammatory processes in cardiovascular complications in OSA [25, 49, 50]. The blood pressure increase in response to IH is also likely mediated by the renin-angiotensin-aldosterone system (RAAS) and both, renal denervation and pharmacological blockage of angiotensin II have recently been shown to prevent IH-mediated blood pressure increases in rodents [51, 52]. IH also promotes atherosclerosis [53, 54] and associated diseases and a recent study reported the promotion of a vasoconstrictive profile in human cultured coronary artery cells in response to this stimulus [55]. The importance of IH-mediated proinflammatory pathway activation in detrimental vascular diseases was again highlighted by Song et al. reporting significant attenuation of atherosclerotic processes in atherosclerotic-prone *ApoE*^{-/-} mice with an additional genetic inhibition of NF- κ B in comparison to standard *ApoE*^{-/-} mice [56]. Interestingly, younger animals appear to be more susceptible to IH-induced cardiac remodelling than older mice [45] and normoxic recovery may reverse these changes [57] raising the possibility that CPAP therapy if provided early in the course of OSA may lead to attenuation of this process. Furthermore, murine studies suggest that IH affects the foetus during maternal gestation and may predispose the adult male offspring to vascular disease which is an important topic requiring further detailed investigations [58, 59].

Considerable advances have also been made in our understanding of the mechanisms of IH-induced insulin resistance, T2D and other glucose disorders and their relevance to OSA [60]. Recently, a randomized crossover trial of CPAP vs. CPAP withdrawal revealed that OSA recurrence promotes an increase in circulating free fatty acids (FFA) and glucose during

sleep, which was associated with sympathetic and adrenocortical activation [61]. Pancreatic β -cell dysfunction and insulin resistance in the insulin target organs adipose tissue, liver and skeletal muscles have been implemented in the pathogenesis of insulin resistance in response to IH. Adipose tissue inflammation is increasingly recognized to play a key role and epididymal lipectomy prevents IH-induced glucose alterations in mice [62, 63]. In lean and diet-induced obese mice as well as cultured cells, the IH-mediated insulin resistance is accompanied by polarization of adipose tissue macrophages towards a proinflammatory phenotype with the net consequence of metabolically dysfunctional adipose tissue [24]. IH also leads to release of free fatty acids (FFA) from adipose tissue into the systemic circulation and chronically elevated levels of FFA may further contribute to impaired glucose metabolism through promotion of insulin resistance in the liver and decreased pancreatic insulin secretion [64]. Continuing the debate of how adipose tissue perceives IH, a recent study compared the effects of IH and sustained hypoxia on the visceral adipose tissue in mice and identified important differences [65]. While sustained hypoxia led to a preferential activation of the hypoxia inducible factor 1 (HIF-1) pathway with adaptive responses to the hypoxic insult, IH induced a proinflammatory phenotype and whitening of the adipose tissue with subsequent insulin resistance. In addition, improvement in glucose function with blockage of the endothelin-1 type B receptor has been reported, thus supporting previous results and identifying a potential therapeutic target [66, 67].

OSA is also associated with the development of NAFLD, independent at least in part of the effects of obesity or shared comorbidities [68, 69]. The degree of nocturnal hypoxia in OSA has been identified as independent predictor of this association and supporting the pivotal role of IH in this process, rodents exposed to IH develop impairment of hepatic lipid metabolism, steatosis and fibrosis [70-72]. The pathogenesis of IH-mediated NAFLD likely includes activation of pro-inflammatory pathways and oxidative stress but remains

incompletely explored. Interestingly, a recent study utilizing cell culture techniques and diet-induced obese mice concluded that hypoxia promotes NAFLD through HIF-2 α -mediated lipogenesis via peroxisome proliferator-activated receptor (PPAR)- α activation [73] and this mechanistic pathway warrants further exploration in the setting of IH.

Pathophysiological Responses of Sleep Disturbances in OSA

Sleep Fragmentation

Normal sleep is essential for a person's health and wellbeing and beside sleep duration, the continuity of sleep is also increasingly recognized in its importance for normal daytime function. In healthy volunteers, experimental sleep fragmentation (SF) has been shown to lead to a decrease in insulin sensitivity and to blunting of the usual nocturnal dip in blood pressure [74, 75]. Furthermore, in a population of 780 healthy elderly subjects repeated sympathetic arousals during sleep were associated with elevated systolic blood pressure and higher risk of hypertension, after controlling for multiple potential confounders [76].

In OSA, SF is a characteristic feature and a consequence of recurrent arousals leading to subsequent excessive daytime sleepiness as the most debilitating daytime symptom in these patients. Arousals in OSA are associated with repetitive substantial blood pressure rises as high as 80 mm Hg [77, 78]. However, the contribution of these acute changes to the development of cardiovascular and metabolic conditions is still under debate. A few studies have cross-sectionally or longitudinally evaluated the association of polysomnographic variables characterising SF, such as the arousal index, with cardiovascular or metabolic outcomes in OSA, and have come to different conclusions. Among 355 children evaluated for sleep-disordered breathing, a high arousal index predicted the presence of endothelial dysfunction [79]. In contrast, in a large prospective study demonstrating an independent relationship between incidence of metabolic syndrome and moderate to severe OSA, only

indices characterizing IH, but not SF, were identified as predictors of this outcome [80]. Similarly, in a cross-sectional analysis of 2,055 participants from the Multi-Ethnic Study of Atherosclerosis, sleep depth as a continuous measure of arousability was not associated with higher blood pressure in contrast to markers of hypoxic burden [81]. Adding to the debate, a Japanese study recently reported an independent association of the arousal index with the presence of carotid intima plaques. However, study population was small and a substantial proportion of subjects suffered from various confounding comorbidities [82]. Thus, the role of SF in cardiometabolic disease processes in OSA remains uncertain. However, the reliability of the arousal index based on a one-night polysomnography as marker of SF is still uncertain and there are no clear normative values of the arousal index in various demographic groups.

The role of SF in cardiometabolic disease processes has also been in the focus of numerous animal studies. In earlier studies using canine or rat models, SF induced by recurrent acoustic arousals failed to contribute to hypertension [83, 84]. However, Launois et al. compared the hemodynamic responses of respiratory and non-respiratory arousals in a porcine model and found, that only respiratory arousals led to blood pressure surges providing a potential explanation for the lack of response in the previous studies [85]. Over the last decade, substantial advances in our understanding of responses to SF have been made by studies utilizing a murine model that requires no direct human interaction and arousals are induced by recurrent minimally stressful tactile stimuli. Long term exposure to this model of SF initiated the development of mild hypertension, endothelial dysfunction and early structural vascular changes in C57Bl/6J wild-type mice and led to a significant progression of atherosclerotic lesion in *Apoe*^{-/-} mice [86, 87]. Furthermore, SF induces insulin resistance predominantly mediated by visceral adipose tissue inflammation [88]. In summary, SF in

mice leads to adverse cardiometabolic consequences but the detailed contribution of this triggering factor in OSA requires further translational studies.

Short Sleep Duration

In recent years there has been mounting evidence of a U-shaped association between both, abnormally short and long sleep duration and numerous adverse health outcomes including mortality and diabetes [89, 90]. Evidence is particularly strong for short sleep duration, defined as a habitual sleep time of ≤ 6 hours, which has been linked with increased morbidity and mortality attributed mainly to adverse cardiometabolic risk including obesity, hypertension, cardiovascular disease and T2D [89, 91-93]. This is of specific public health concern, as sleep duration has been declining in the last few decades and approximately 35% of the general population sleep less than 6 hours per night [94, 95]. In particular, various cross-sectional and prospective studies have linked short sleep duration to increased prevalence and incidence of insulin resistance and T2D [90, 96, 97] and a meta-analysis on this topic revealed that self-reported sleeping ≤ 5 hours imposed a 45% increase in the risk of diabetes [97]. Furthermore, insufficient sleep is associated with poorer glycemic control in diabetic subjects and may also be related to poorer diabetes self-care behaviors leading to recommendations by the American Diabetes Association to include evaluation of sleep duration and pattern as part of comprehensive diabetes care [98, 99]. In support of a causal relationship between short sleep and metabolic dysregulation, experimental sleep restriction in humans leads to increased calorie intake, weight gain, insulin resistance and possibly impaired insulin secretion with sympathetic excitation, inflammation, changes in the composition of the gut microbiota and alterations of the 24-hour cortisol profile with blunting of the usual nocturnal decline proposed to be the underlying mechanistic links [100-102]. However, some of these alterations have been found to be transient and how these results correlate with diabetes as a consequence of long-term sleep restriction remains unknown. In

addition, studies evaluating the benefit of experimental sleep extension on glucose metabolisms have yielded conflicting results [103-107]. However, the ability of subjects to extend their sleep time greatly varies and a recent cross-over study on 21 short-sleeping healthy participants revealed that only those who could sleep more than 6 hours during sleep extension showed improvement of fasting insulin resistance and β -cell function [106]. Thus, there are still unanswered questions surrounding the association of sleep duration with cardiometabolic diseases and we require further large-scale well-designed epidemiological and translational studies before definite conclusions can be drawn.

The specific role of short sleep in OSA and its relative contribution to the pathophysiology of cardiometabolic co-morbidities are also as yet unclear. Several studies using wrist actigraphy or polysomnography as tools to measure sleep length have identified shorter sleep in OSA subjects in comparison to non-OSA counterparts [108, 109]. However, data from the ELSA-Brasil cohort, comprising of over 2,000 participants, revealed only a significant association of OSA, but not sleep duration, with prevalent obesity, hypertension and dyslipidaemia [108]. Similarly, a recent cross-sectional analysis of the Nagahama study of over 7,000 subjects identified an independent association of OSA and obesity, but not of actigraphy-evaluated sleep duration, with prevalent diabetes and hypertension [110]. In contrast, Ren et al found that in subjects with OSA, objectively measured sleep duration of 5-6 hours and < 5 hours increased the odds of prevalent hypertension by 45% and 80%, respectively [111]. Furthermore, in a prospective study of over 13,000 subjects with recent acute coronary syndrome, both, OSA and short sleep were identified as independent predictors of major coronary events, however, the reliance on the Berlin questionnaire and subjectively reported sleep time were substantial limitations [112].

Circadian Misalignment

All life on Earth benefits from an internal timing mechanism to permit adaptations to the predictive changes from day to night, and this is termed the circadian clock. Most cells of the immune system have an intact clock, and inflammatory and immune parameters frequently show circadian control, including vaccine responses, innate inflammatory reactions, and aspects of the adaptive immune response [113-115]. Manipulations of the core clock machinery, or environmental disruptions, such as changes to the lighting schedule or fast/feeding cycles, result in changes to the immune response with in most cases an exaggerated inflammatory component [116]. In mammals, the internal circadian clock is synchronised to the external light-dark environment through a retinal pathway to the central clock in the brain. The central clock, the suprachiasmatic nucleus, then entrains peripheral clocks through neural and humoral pathways [117] (Figure 2).

Circadian rhythms influence virtually all aspects of physiological architecture and chronic disruptions, as for instance seen in shift workers, have been linked to obesity, metabolic derangements, cardiovascular diseases, mood disorders or cancers [118-121]. Laboratory studies using forced circadian misalignment have lend support to this evidence demonstrating insulin resistance, inverted cortisol rhythms, and increased blood pressure in participants subjected to this protocol [122, 123].

The circadian rhythm and sleep are mutually linked in a bidirectional relationship. The sleep-wake cycle is one of the most prominent circadian-regulated behaviours and the circadian clock acts as a gating mechanism to confine sleep to specific parts of the diurnal cycle [124, 125]. Genetic disruptions of the clock lead to alterations of physiological sleep regulation. At the same time, changes in sleep timing or duration can feedback on clock function and experimental studies have demonstrated that sleep curtailment or mistiming strongly affects molecular correlates of the circadian clock [126-129].

Given the profound sleep disturbances in OSA, disruptions in clock oscillations are also likely. However, surprisingly, the prevalence of circadian misalignments in OSA is hardly investigated and the potential contribution of this trait to cardiometabolic comorbidities has been largely neglected. Some studies have demonstrated alterations of the normal circadian variations of blood pressure, arterial stiffness as well as circulating cytokines, hormones, prothrombotic and fibrinolytic markers in OSA subjects compared to controls with improvement following effective CPAP therapy [130-135]. Furthermore, Martinez-Nicholas et al. evaluated the circadian rhythm of distal skin temperature and identified significant alterations in OSA with lower temperature at night in comparison to controls and these disturbances correlated with the severity of the disease and improved with CPAP therapy. Moreover, these changes correlated with the level of daytime sleepiness and the authors suggested that the measurement of skin temperature may facilitate understanding of the pathophysiology of sleepiness in these patients [136].

Beside disruptions of peripheral tissue clocks there is also limited evidence of an impact of OSA on central clock function. Burioka et al. reported a blunted daily variability of the expression of the master clock-regulating gene *Period1 (PER1)* in leukocytes of OSA subjects versus matched controls with higher levels at night-time and restoration of the normal pattern with CPAP [137]. In addition, OSA adversely affects melatonin secretion. Synthesized by the pineal gland, melatonin production and secretion are directly dependent on the ambient light-dark cycle and hence, melatonin is a main output signal of the central circadian pacemaker, the suprachiasmatic nucleus [138]. Alteration of the pattern of melatonin secretion with loss of the nocturnal peak has been reported in OSA subjects. However, studies so far have failed to show a benefit on this finding with CPAP therapy [139].

In summary, circadian disruptions in OSA are poorly understood and the identification of the detailed contribution of these processes to cardiometabolic disease processes is a major research priority and targeting these alterations may identify important novel treatment approaches.

Hypercapnia – a forgotten dimension

Repetitive episodes of hypoxia and reoxygenation in OSA are inextricably coupled with oscillations in the partial pressure of carbon dioxide (CO₂) ranging from hypocapnia to hypercapnia. Notably, hypercapnia in combination with hypoxia results in increased sympathetic activity which is not seen with hypocapnic hypoxia [140]. In contrast to IH, the consequences of intermittent hypercapnia are poorly understood and the potentially pathophysiological and modifying roles of this identity in OSA patients, which are predominantly eucapnic during daytime have been grossly ignored. This is partly attributable to the fact that CO₂ monitoring is currently not routinely used in clinical practice and methods such as end-tidal or transcutaneous CO₂ measurements have significant limitations. Furthermore, most commonly used animal models have focused on IH without controlling for CO₂. However, extrapolating from other respiratory conditions there is now ample evidence suggesting possibly important pathophysiological responses to hypercapnia. Depending on the clinical scenario, the consequences of high CO₂ have been referred to as a “double-edged sword” with the potential to be both detrimental and beneficial for patients. Hypercapnia is an independent predictor of mortality in Chronic Obstructive Pulmonary Disease (COPD) and in patients with Acute Respiratory Distress Syndrome (ARDS) admitted to the intensive care unit [141, 142]. Furthermore, studies in mice demonstrate that hypercapnia is damaging in the context of a bacterial challenge, likely as a consequence of CO₂-dependent immunosuppression [143]. Conversely, mild hypercapnia as results of a protective ventilation

strategy improves mortality in ARDS patients which has led to the concept of “permissive hypercapnia” [144, 145]. In support, murine studies have demonstrated hypercapnia-associated acidosis to be markedly protective in the context of a lipopolysaccharide (LPS)-induced destructive inflammatory challenge and in stretch-induced lung injury [146, 147]. Although this field is still in its infancy, there is emerging knowledge of how altered CO₂ levels affect cell signalling and gene expression and subsequent immunity and inflammation. Studies from model organisms and cell cultures indicate that hypercapnia elicits changes in cellular signalling and gene expression in a variety of different cell types, e.g. lung epithelium [148, 149], smooth muscle [150], skeletal muscle [151] and monocytes [152]. These changes are thought to be independent of hypercapnia-associated acidosis and reveal distinct clusters of differentially expressed genes from those elicited by hypoxia. Notably, genes associated with the immune response (e.g. Rel-dependent antimicrobial peptides) are differentially expressed in hypercapnia. To date, a master regulator of CO₂-dependent gene expression, analogous to HIF for the hypoxia response, has not been identified. However, work on the nuclear factor NF-κB pathway has revealed sensitivity of both the canonical (RelA-dependent) and non-canonical (RelB-dependent) pathway to CO₂. In particular, non-canonical NF-κB family members, such as IKKα, RelB and p100 are sensitive to CO₂, independent of an external inflammatory stimulus supporting a potentially important role of this pathway in immune regulation [149, 153, 154].

Thus, hypercapnia is much more than a simple waste product of aerobic respiration. CO₂ has the ability to elicit changes in gene expression, particularly those associated with immune and inflammatory signalling. These findings imply that CO₂ is likely a highly relevant dimension in OSA and the role of hypercapnia should be given greater consideration in the future, particularly in the context of immune regulation. As we strive to better understand the pathophysiological mechanisms of OSA-associated cardiometabolic

complications we must give due consideration to the role of circulating CO₂ levels and control for altered CO₂ levels in our models.

What next: CPAP for everyone or personalized treatments?

As extensively discussed in the Research Seminar and summarized in this perspective, the pathophysiology of cardiovascular and metabolic diseases in OSA is complex and remains incompletely understood. It has become increasingly clear that focusing on single mechanistic traits is too simplistic. Most research into this subject so far has been directed to IH and SF as dominant triggering factors. Intrathoracic pressure swings as a result of forced inspiration against an occluded upper airway leading to shear stress on the heart and intrathoracic blood vessels have also been recognized to contribute to adverse consequences, in particular to atrial fibrillation and heart failure [155-157]. Other features such as alterations in sleep beyond disruptions as consequence of recurrent arousals as well as intermittent changes in CO₂ partial pressure may play important detrimental or attenuating roles and there is likely considerable interaction between those mechanistic pathways. Furthermore, many modifying factors such as age, sex, genetic makeup, anthropometric features, physical activity or comorbid conditions which are frequent in OSA may influence disease processes. In addition, there is likely a substantial influence with diet. Above all, cardiometabolic disease process are considerably amplified in the presence of a high-fat diet, potentially mediated through alteration of the gut microbiome, and this interaction will require further attention in future studies [158, 159] (Figure 3).

While past and current experimental models have been fundamental to our understanding of the direct consequences of single pathophysiological triggering factors, there are, however, too simplistic to reflect the clinical condition of OSA in all its complexity. Thus, not surprisingly, results obtained from pre-clinical models often failed to

translate into human populations and consequently, this has left us with limited knowledge of potential therapeutic targets. Furthermore, OSA is a very heterogeneous condition characterized by a wide diversity of clinical symptoms and presentations. Several cluster analyses have identified a variety of different clinical and polysomnographic phenotypes and between those OSA subgroups, there is considerable variability in age, obesity, the degree of sleepiness and burden of co-morbidities [160-163]. Importantly, clusters substantially differ in their susceptibility to adverse cardiovascular complications [162] and thus, detailed understanding of the mechanisms underlying cardiometabolic disease processes with identification of these different phenotypes in OSA are crucial steps for the detection of effective treatment strategies. CPAP therapy is the treatment of choice for the majority of OSA patients. It improves sleepiness, quality of life and neurocognitive function but its benefit on cardiovascular and metabolic outcomes is uncertain. Controversy remains especially of the usefulness of CPAP therapy in minimally symptomatic or asymptomatic OSA patients, recently highlighted in excellent Pro/Con debates [164-167]. Although CPAP has demonstrated its positive effects on early cardiovascular disease processes, i.e. endothelial dysfunction [168, 169], blood pressure control [170] or insulin resistance [171, 172], several recent randomized controlled trials, despite their limitations, have questioned its efficacy in preventing cardiac events in patients with established cardiovascular disease [173-177]. The effectiveness of CPAP may vary depending on the phenotype and, for example, 25-30% of OSA patients with adequate adherence to CPAP treatment (>4 hours per night) do not benefit from CPAP treatment in blood pressure control and some may even experience an increase [178-180]. Following a post-hoc analysis of the SAVE study, cluster analysis suggested that OSA patients with multimorbidity (OSA combined with diabetes and/or several cardiovascular disease) may benefit most from CPAP therapy [181]. Data from the Spanish Sleep Network revealed that in OSA patients with resistant hypertension a single

cluster of cardiovascular system–related functional miRNA’s distinguished CPAP responders to non-responders suggesting the usefulness of such epigenetic biomarkers in the guidance of personalized treatments and this field requires further exploration [182]. The benefits of available alternative single treatment strategies for OSA on cardiometabolic processes are also unclear. Mandibular advance devices (MAD) are an effective alternative to CPAP especially for patients with moderate disease or poor adaptation to CPAP. There is evidence of blood pressure reduction with MAD but the effect on other disease processes remains unexplored [183]. Undoubtedly, we need to identify therapeutic approaches targeted to the needs and characteristics of individual patients through implementation of personalized medicine and OSA-specific treatments need to be embedded in a multidisciplinary management in conjunction with lifestyle measures and optimal pharmaceutical treatments for comorbid conditions. As supported by a recent American Thoracic Society (ATS) clinical practice guideline, weight reduction should be incorporated into the management of all overweight and obese OSA patients [184] and CPAP combined with weight loss leads to incremental reductions in blood pressure and insulin resistance [185]. However, weight loss is difficult to achieve with conventional measures alone and bariatric surgery, although effective in achieving weight reduction and metabolic improvements, is not a suitable intervention for everyone. A Liraglutide-facilitated weight loss regimen may be an intriguing alternative [186], but further studies are needed to explore this approach in OSA. Long-term increased physical exercise is also associated with weight loss and in addition, leads to improvement in blood pressure, and hence, should also be part of an integrated care plan [187, 188].

An optimal treatment approach also includes targeted pharmacological treatment of cardiovascular risk factors and co-morbidities. This has been best studied in the setting of

hypertension and while antihypertensive drugs are far more effective than CPAP therapy in lowering blood pressure, there is added benefit with CPAP therapy [189].

Finally, targeting daytime sleepiness which has been suggested as an independent predictor of adverse cardiovascular outcomes in OSA [162] may be an alternative treatment approach. Several pharmacological agents including Modafinil, Solriamfetol or Pitolisant have shown to improve sleepiness in OSA patients and future studies evaluating the benefit of these agents on cardiometabolic endpoints are required [190-192].

Concluding remarks and future directions

The future of medicine relies on the ability to assess disease risk at an individual level, the understanding of molecular mechanisms underlying progression of disease and aggregation of comorbidities and early initiation of personalized interventions [193]. The ERS research seminar “Targeting the detrimental effects of sleep disturbances and disorders” held in Dublin in 2019 was a founding event for stimulating scientific exchanges and eliciting a European research consortium at the critical mass. The common objective was to address the biological mechanisms of consequences of OSA in a continuum from molecules to cells, tissues, organs, systems, persons and impact on populations. The overarching goals for improving OSA management include the identification of significant OSA phenotypes and actionable pathways mediating cardiometabolic consequences, and to facilitate the development of innovative therapeutic approaches.

To achieve these goals of precision and personalized medicine in OSA and to formulate advice for value-based care, the following approaches will be prerequisites:

- A first step already ongoing is the innovative use of real world data [194, 195], well-managed cohorts and wearable monitoring [196] for enabling physiological profiling and identification of homogeneous OSA groups of interest (i.e. main OSA clusters

composed of relevant individual, social and environmental context factors and their interdependencies). The absence of definition of these relevant phenotypes might be a reason that large CPAP randomized controlled trials have shown no or modest effects on reduction of late cardiovascular events [173, 174, 197].

- Large randomized controlled trials have failed to show benefit of CPAP therapy on cardiovascular outcomes, however, as highlighted in the previous chapter, they had significant limitations and in the majority of studies the most appropriate, i.e. sleepy, patients for treatment were excluded leaving us with numerous questions and uncertainties. Realistically, further large RCTs will be difficult to conduct in the field as the costs are prohibitive with unacceptable delays before getting the answer. Thus, there is a crucial need to implement innovations in clinical research methods for reducing costs and increasing productivity. Recently, alternative solutions have been proposed including conducting randomized trials in existing cohorts [198], usage of Electronic Health Records (EMR) to derive control arms [199], and/or use of new statistical methods such as causal inference to affirm causality from observational data [199].
- Cell culture, animal and human models of IH exposures need to be technically improved by including hypercapnia as an associated stimulus. Less severe and more clinically relevant forms of IH exposure should also be considered in murine models to better understand adaptive and detrimental effects in OSA and findings should also be reproduced in different species. Organ-on-a-chips multi-channel 3-D microfluidic cell cultures will be a step forward to simulate the activities, mechanics and physiological responses of entire organs to IH allowing to overcome the current limitations of conventional cell culture paradigms. The combination of sleep fragmentation/deprivation and circadian misalignment with IH exposures is also

crucial to truly represent the multiple OSA clinical scenarios. These methodological improvements have the potential to allow identification of clinically relevant molecular pathways and to discover new pharmacological targets with their respective companion biomarkers in the near future. Such developments will contest the current paradigm for management of OSA largely reflecting a “one-size-fits-all” approach whereby a large majority of patients are exclusively treated with CPAP without appropriate combined therapies targeting OSA-related organ-specific damages.

- Progression and accumulation of comorbidities during OSA life courses need to be better characterized and anticipated to define disease activity and delineate early and personalized interventions. This requires deep longitudinal profiling implying to make repeated deep phenotyping evaluations available and to longitudinally collect multiple bio-samples analyzed with multi-omics strategies. In addition, we require reliable markers predicting cardiometabolic outcomes which may guide treatment decisions. The recently identified hypoxic burden derived from overnight polysomnography is a promising indicator, but it requires further large longitudinal studies.
- Artificial intelligence will be fundamental for harnessing the dynamics and heterogeneity of OSA longitudinal trajectories [200, 201]. It may provide unique insights for organizing the huge diversity of factors contributing to individual OSA patients’ trajectories into a rational framework amenable for clinical decision, therapeutic intervention and reform of the health system.
- Furthermore, diagnostic and therapeutic pathways will be completely reshaped by new automated methods and artificial intelligence. This will be the case for new techniques for identifying abnormal respiratory events during sleep [202] or new methods for analysing sleep electroencephalogram [203]. Finally, the interest of

repeated patient profiling is supported by intra-subject night-to-night variability in OSA severity impacting on the occurrence of major outcomes [204].

To achieve these ambitious goals for OSA patients and the society, structuration of international consortiums is absolutely required and the ERS seminar was a critical step into this direction.

Acknowledgement

This perspective is based on the data presented and discussed during the European Respiratory Society (ERS) Research Seminar “Targeting the detrimental effects of sleep disturbances and disorders”. The seminar was organized by Silke Ryan (Dublin, Ireland, Chair) and Isaac Almendros (Barcelona, Spain, Co-Chair). The organizers would like to thank the faculty members, chairs and all participants for their active contribution, interaction, and fruitful discussions (full presentations from the ERS research seminar can be downloaded from <http://www.ers-education.org/events/research-seminars.aspx> and a list of all participants is available in the online supplement). The seminar was sponsored by the ERS with additional financial support of unrestricted grants from ResMed PEI (Ireland), AirLiquide Healthcare (Ireland) and Philips Respironics. A special thanks goes to Céline Marques Grunho, Sandy Borlat and Alexandre Delarge (ERS, Lausanne, Switzerland) for their outstanding logistical support.

References

1. Levy P, Kohler M, McNicholas WT, Barbe F, McEvoy RD, Somers VK, Lavie L, Pepin JL. Obstructive sleep apnoea syndrome. *Nat Rev Dis Primers* 2015; 1: 15015.
2. Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, Nunez CM, Patel SR, Penzel T, Pepin JL, Peppard PE, Sinha S, Tufik S, Valentine K, Malhotra A.

- Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. *Lancet Respir Med* 2019; 7(8): 687-698.
3. Kent BD, Grote L, Ryan S, Pepin JL, Bonsignore MR, Tkacova R, Saaresranta T, Verbraecken J, Levy P, Hedner J, McNicholas WT, collaborators E. Diabetes mellitus prevalence and control in sleep-disordered breathing: the European Sleep Apnea Cohort (ESADA) study. *Chest* 2014; 146(4): 982-990.
 4. McNicholas WT, Bonsignore MR. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2007; 29(1): 156-178.
 5. Punjabi NM, Caffo BS, Goodwin JL, Gottlieb DJ, Newman AB, O'Connor GT, Rapoport DM, Redline S, Resnick HE, Robbins JA, Shahar E, Unruh ML, Samet JM. Sleep-disordered breathing and mortality: a prospective cohort study. *PLoS Med* 2009; 6(8): e1000132.
 6. Ryan S. Mechanisms of cardiovascular disease in obstructive sleep apnoea. *J Thorac Dis* 2018; 10(Suppl 34): S4201-S4211.
 7. Cummins EP. Physiological gases in health and disease - key regulatory factors, not just a lot of hot air. *J Physiol* 2017; 595(8): 2421-2422.
 8. Baguet JP, Hammer L, Levy P, Pierre H, Launois S, Mallion JM, Pepin JL. The severity of oxygen desaturation is predictive of carotid wall thickening and plaque occurrence. *Chest* 2005; 128(5): 3407-3412.
 9. Ryan S, Taylor CT, McNicholas WT. Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. *Am J Respir Crit Care Med* 2006; 174(7): 824-830.
 10. Tkacova R, McNicholas WT, Javorsky M, Fietze I, Sliwinski P, Parati G, Grote L, Hedner J, European Sleep Apnoea Database study c. Nocturnal intermittent hypoxia predicts prevalent hypertension in the European Sleep Apnoea Database cohort study. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2014; 44(4): 931-941.
 11. Azarbarzin A, Sands SA, Stone KL, Taranto-Montemurro L, Messineo L, Terrill PI, Ancoli-Israel S, Ensrud K, Purcell S, White DP, Redline S, Wellman A. The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study. *Eur Heart J* 2019; 40(14): 1149-1157.
 12. Kim JS, Azarbarzin A, Wang R, Djonlagic IE, Punjabi NM, Zee PC, Koo BB, Soliman EZ, Younes M, Redline S. Association of novel measures of sleep disturbances with blood pressure: the Multi-Ethnic Study of Atherosclerosis. *Thorax* 2020; 75(1): 57-63.
 13. Chopra S, Polotsky VY, Jun JC. Sleep Apnea Research in Animals. Past, Present, and Future. *Am J Respir Cell Mol Biol* 2016; 54(3): 299-305.
 14. Davis EM, O'Donnell CP. Rodent models of sleep apnea. *Respir Physiol Neurobiol* 2013; 188(3): 355-361.
 15. Dematteis M, Godin-Ribuot D, Arnaud C, Ribuoat C, Stanke-Labesque F, Pepin JL, Levy P. Cardiovascular consequences of sleep-disordered breathing: contribution of animal models to understanding the human disease. *ILAR J* 2009; 50(3): 262-281.
 16. Farre R, Montserrat JM, Gozal D, Almendros I, Navajas D. Intermittent Hypoxia Severity in Animal Models of Sleep Apnea. *Front Physiol* 2018; 9: 1556.
 17. Hamrahi H, Chan B, Horner RL. On-line detection of sleep-wake states and application to produce intermittent hypoxia only in sleep in rats. *J Appl Physiol (1985)* 2001; 90(6): 2130-2140.

18. Tagaito Y, Polotsky VY, Campen MJ, Wilson JA, Balbir A, Smith PL, Schwartz AR, O'Donnell CP. A model of sleep-disordered breathing in the C57BL/6J mouse. *J Appl Physiol (1985)* 2001; 91(6): 2758-2766.
19. Servick K. Of mice and microbes. *Science* 2016; 353(6301): 741-743.
20. Farre R, Rotger M, Montserrat JM, Calero G, Navajas D. Collapsible upper airway segment to study the obstructive sleep apnea/hypopnea syndrome in rats. *Respir Physiol Neurobiol* 2003; 136(2-3): 199-209.
21. Nacher M, Serrano-Mollar A, Farre R, Panes J, Segui J, Montserrat JM. Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. *Respir Physiol Neurobiol* 2007; 155(1): 93-96.
22. Campillo N, Jorba I, Schaedel L, Casals B, Gozal D, Farre R, Almendros I, Navajas D. A Novel Chip for Cyclic Stretch and Intermittent Hypoxia Cell Exposures Mimicking Obstructive Sleep Apnea. *Front Physiol* 2016; 7: 319.
23. Minoves M, Morand J, Perriot F, Chatard M, Gonthier B, Lemarie E, Menut JB, Polak J, Pepin JL, Godin-Ribuot D, Briancon-Marjollet A. An innovative intermittent hypoxia model for cell cultures allowing fast Po₂ oscillations with minimal gas consumption. *Am J Physiol Cell Physiol* 2017; 313(4): C460-C468.
24. Murphy AM, Thomas A, Crinion SJ, Kent BD, Tambuwala MM, Fabre A, Pepin JL, Roche HM, Arnaud C, Ryan S. Intermittent hypoxia in obstructive sleep apnoea mediates insulin resistance through adipose tissue inflammation. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2017; 49(4).
25. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. *Circulation* 2005; 112(17): 2660-2667.
26. Tamisier R, Gilmartin GS, Launois SH, Pepin JL, Nespoulet H, Thomas R, Levy P, Weiss JW. A new model of chronic intermittent hypoxia in humans: effect on ventilation, sleep, and blood pressure. *J Appl Physiol (1985)* 2009; 107(1): 17-24.
27. Tamisier R, Pepin JL, Remy J, Baguet JP, Taylor JA, Weiss JW, Levy P. 14 nights of intermittent hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2011; 37(1): 119-128.
28. Pialoux V, Hanly PJ, Foster GE, Brugniaux JV, Beaudin AE, Hartmann SE, Pun M, Duggan CT, Poulin MJ. Effects of exposure to intermittent hypoxia on oxidative stress and acute hypoxic ventilatory response in humans. *Am J Respir Crit Care Med* 2009; 180(10): 1002-1009.
29. Faiss R, Girard O, Millet GP. Advancing hypoxic training in team sports: from intermittent hypoxic training to repeated sprint training in hypoxia. *Br J Sports Med* 2013; 47 Suppl 1: i45-50.
30. Gangwar A, Pooja, Sharma M, Singh K, Patyal A, Bhaumik G, Bhargava K, Sethy NK. Intermittent normobaric hypoxia facilitates high altitude acclimatization by curtailing hypoxia-induced inflammation and dyslipidemia. *Pflugers Arch* 2019; 471(7): 949-959.
31. Manukhina EB, Belkina LM, Terekhina OL, Abramochkin DV, Smirnova EA, Budanova OP, Mallet RT, Downey HF. Normobaric, intermittent hypoxia conditioning is cardio- and vasoprotective in rats. *Exp Biol Med (Maywood)* 2013; 238(12): 1413-1420.
32. Meng SX, Wang B, Li WT. Intermittent hypoxia improves cognition and reduces anxiety-related behavior in APP/PS1 mice. *Brain Behav* 2019; e01513.
33. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation* 1986; 74(5): 1124-1136.

34. Serebrovska TV, Portnychenko AG, Drevytska TI, Portnichenko VI, Xi L, Egorov E, Gavalko AV, Naskalova S, Chizhova V, Shatylo VB. Intermittent hypoxia training in prediabetes patients: Beneficial effects on glucose homeostasis, hypoxia tolerance and gene expression. *Exp Biol Med (Maywood)* 2017; 242(15): 1542-1552.
35. Wang H, Shi X, Schenck H, Hall JR, Ross SE, Kline GP, Chen S, Mallet RT, Chen P. Intermittent Hypoxia Training for Treating Mild Cognitive Impairment: A Pilot Study. *Am J Alzheimers Dis Other Demen* 2020; 35: 1533317519896725.
36. El-Chami M, Sudan S, Lin HS, Mateika JH. Exposure to intermittent hypoxia and sustained hypercapnia reduces therapeutic CPAP in participants with obstructive sleep apnea. *J Appl Physiol (1985)* 2017; 123(4): 993-1002.
37. Almendros I, Wang Y, Gozal D. The polymorphic and contradictory aspects of intermittent hypoxia. *Am J Physiol Lung Cell Mol Physiol* 2014; 307(2): L129-140.
38. Lavie L. Oxidative stress in obstructive sleep apnea and intermittent hypoxia--revisited--the bad ugly and good: implications to the heart and brain. *Sleep Med Rev* 2015; 20: 27-45.
39. Gileles-Hillel A, Almendros I, Khalyfa A, Nigdelioglu R, Qiao Z, Hamanaka RB, Mutlu GM, Akbarpour M, Gozal D. Prolonged Exposures to Intermittent Hypoxia Promote Visceral White Adipose Tissue Inflammation in a Murine Model of Severe Sleep Apnea: Effect of Normoxic Recovery. *Sleep* 2017; 40(3).
40. Gozal D, Khalyfa A, Qiao Z, Almendros I, Farre R. Temporal trajectories of novel object recognition performance in mice exposed to intermittent hypoxia. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2017; 50(6).
41. Geovanini GR, Wang R, Weng J, Jenny NS, Shea S, Allison M, Libby P, Redline S. Association between Obstructive Sleep Apnea and Cardiovascular Risk Factors: Variation by Age, Sex, and Race. The Multi-Ethnic Study of Atherosclerosis. *Ann Am Thorac Soc* 2018; 15(8): 970-977.
42. Vgontzas AN, Li Y, He F, Fernandez-Mendoza J, Gaines J, Liao D, Basta M, Bixler EO. Mild-to-moderate sleep apnea is associated with incident hypertension: age effect. *Sleep* 2019; 42(4).
43. Zhao YY, Javaheri S, Wang R, Guo N, Koo BB, Stein JH, Korcarz CE, Redline S. Associations Between Sleep Apnea and Subclinical Carotid Atherosclerosis: The Multi-Ethnic Study of Atherosclerosis. *Stroke* 2019; STROKEAHA118022184.
44. Cubillos-Zapata C, Balbas-Garcia C, Avendano-Ortiz J, Toledano V, Torres M, Almendros I, Casitas R, Zamarron E, Garcia-Sanchez A, Feliu J, Aguirre LA, Farre R, Lopez-Collazo E, Garcia-Rio F. Age-dependent hypoxia-induced PD-L1 upregulation in patients with obstructive sleep apnoea. *Respirology* 2019; 24(7): 684-692.
45. Castro-Grattoni AL, Suarez-Giron M, Benitez I, Torres M, Almendros I, Farre R, Montserrat JM, Dalmases M, Gozal D, Sanchez-de-la-Torre M, Spanish Sleep N. Effect of age on the cardiovascular remodelling induced by chronic intermittent hypoxia as a murine model of sleep apnoea. *Respirology* 2019; [Epub ahead of print].
46. Gottlieb DJ, Punjabi NM, Mehra R, Patel SR, Quan SF, Babineau DC, Tracy RP, Rueschman M, Blumenthal RS, Lewis EF, Bhatt DL, Redline S. CPAP versus oxygen in obstructive sleep apnea. *N Engl J Med* 2014; 370(24): 2276-2285.
47. Mills PJ, Kennedy BP, Loreda JS, Dimsdale JE, Ziegler MG. Effects of nasal continuous positive airway pressure and oxygen supplementation on norepinephrine kinetics and cardiovascular responses in obstructive sleep apnea. *J Appl Physiol (1985)* 2006; 100(1): 343-348.
48. Turnbull CD, Sen D, Kohler M, Petousi N, Stradling JR. Effect of Supplemental Oxygen on Blood Pressure in Obstructive Sleep Apnea (SOX). A Randomized

- Continuous Positive Airway Pressure Withdrawal Trial. *Am J Respir Crit Care Med* 2019; 199(2): 211-219.
49. Turnbull CD, Lee LY, Starkey T, Sen D, Stradling J, Petousi N. Transcriptomics Identify a Unique Intermittent Hypoxia Mediated Profile in Obstructive Sleep Apnea. *Am J Respir Crit Care Med* 2019.
 50. Ryan S, Taylor CT, McNicholas WT. Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? *Thorax* 2009; 64(7): 631-636.
 51. Kim SJ, Fong AY, Pilowsky PM, Abbott SBG. Sympathoexcitation following intermittent hypoxia in rat is mediated by circulating angiotensin II acting at the carotid body and subfornical organ. *J Physiol* 2018; 596(15): 3217-3232.
 52. Takahashi K, Ueda S, Kobayashi T, Nishiyama A, Fujisawa Y, Sugaya T, Shiota S, Takahashi K, Gohda T, Horikoshi S, Suzuki Y. Chronic intermittent hypoxia-mediated renal sympathetic nerve activation in hypertension and cardiovascular disease. *Sci Rep* 2018; 8(1): 17926.
 53. Arnaud C, Poulain L, Levy P, Dematteis M. Inflammation contributes to the atherogenic role of intermittent hypoxia in apolipoprotein-E knock out mice. *Atherosclerosis* 2011; 219(2): 425-431.
 54. Jun J, Reinke C, Bedja D, Berkowitz D, Bevans-Fonti S, Li J, Barouch LA, Gabrielson K, Polotsky VY. Effect of intermittent hypoxia on atherosclerosis in apolipoprotein E-deficient mice. *Atherosclerosis* 2010; 209(2): 381-386.
 55. Sharma P, Dong Y, Somers VK, Peterson TE, Zhang Y, Wang S, Li G, Singh P. Intermittent hypoxia regulates vasoactive molecules and alters insulin-signaling in vascular endothelial cells. *Sci Rep* 2018; 8(1): 14110.
 56. Song D, Fang G, Mao SZ, Ye X, Liu G, Miller EJ, Greenberg H, Liu SF. Selective inhibition of endothelial NF-kappaB signaling attenuates chronic intermittent hypoxia-induced atherosclerosis in mice. *Atherosclerosis* 2018; 270: 68-75.
 57. Castro-Grattoni AL, Alvarez-Buue R, Torres M, Farre R, Montserrat JM, Dalmases M, Almendros I, Barbe F, Sanchez-de-la-Torre M. Intermittent Hypoxia-Induced Cardiovascular Remodeling Is Reversed by Normoxia in a Mouse Model of Sleep Apnea. *Chest* 2016; 149(6): 1400-1408.
 58. Almendros I, Martinez-Ros P, Farre N, Rubio-Zaragoza M, Torres M, Gutierrez-Bautista AJ, Carrillo-Poveda JM, Sopena-Juncosa JJ, Gozal D, Gonzalez-Bulnes A, Farre R. Placental oxygen transfer reduces hypoxia-reoxygenation swings in fetal blood in a sheep model of gestational sleep apnea. *J Appl Physiol (1985)* 2019; 127(3): 745-752.
 59. Badran M, Yassin BA, Lin DTS, Kobor MS, Ayas N, Laher I. Gestational intermittent hypoxia induces endothelial dysfunction, reduces perivascular adiponectin and causes epigenetic changes in adult male offspring. *J Physiol* 2019; 597(22): 5349-5364.
 60. Kent BD, McNicholas WT, Ryan S. Insulin resistance, glucose intolerance and diabetes mellitus in obstructive sleep apnoea. *J Thorac Dis* 2015; 7(8): 1343-1357.
 61. Chopra S, Rathore A, Younas H, Pham LV, Gu C, Beselman A, Kim IY, Wolfe RR, Perin J, Polotsky VY, Jun JC. Obstructive Sleep Apnea Dynamically Increases Nocturnal Plasma Free Fatty Acids, Glucose, and Cortisol During Sleep. *J Clin Endocrinol Metab* 2017; 102(9): 3172-3181.
 62. Poulain L, Mathieu H, Thomas A, Borel AL, Remy C, Levy P, Arnaud C, Dematteis M. Intermittent hypoxia-induced insulin resistance is associated with alterations in white fat distribution. *Sci Rep* 2017; 7(1): 11180.
 63. Ryan S, Arnaud C, Fitzpatrick SF, Gaucher J, Tamisier R, Pepin JL. Adipose tissue as a key player in obstructive sleep apnoea. *Eur Respir Rev* 2019; 28(152).

64. Weiszenstein M, Shimoda LA, Koc M, Seda O, Polak J. Inhibition of Lipolysis Ameliorates Diabetic Phenotype in a Mouse Model of Obstructive Sleep Apnea. *Am J Respir Cell Mol Biol* 2016; 55(2): 299-307.
65. Gozal D, Gileles-Hillel A, Cortese R, Li Y, Almendros I, Qiao Z, Khalyfa AA, Andrade J, Khalyfa A. Visceral White Adipose Tissue after Chronic Intermittent and Sustained Hypoxia in Mice. *Am J Respir Cell Mol Biol* 2017; 56(4): 477-487.
66. Polak J, Punjabi NM, Shimoda LA. Blockade of Endothelin-1 Receptor Type B Ameliorates Glucose Intolerance and Insulin Resistance in a Mouse Model of Obstructive Sleep Apnea. *Front Endocrinol (Lausanne)* 2018; 9: 280.
67. Briancon-Marjollet A, Monneret D, Henri M, Hazane-Puch F, Pepin JL, Faure P, Godin-Ribuot D. Endothelin regulates intermittent hypoxia-induced lipolytic remodelling of adipose tissue and phosphorylation of hormone-sensitive lipase. *J Physiol* 2016; 594(6): 1727-1740.
68. Aron-Wisnewsky J, Minville C, Tordjman J, Levy P, Bouillot JL, Basdevant A, Bedossa P, Clement K, Pepin JL. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. *Journal of hepatology* 2012; 56(1): 225-233.
69. Polotsky VY, Patil SP, Savransky V, Laffan A, Fonti S, Frame LA, Steele KE, Schweitzer MA, Clark JM, Torbenson MS, Schwartz AR. Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. *Am J Respir Crit Care Med* 2009; 179(3): 228-234.
70. Kang HH, Kim IK, Lee HI, Joo H, Lim JU, Lee J, Lee SH, Moon HS. Chronic intermittent hypoxia induces liver fibrosis in mice with diet-induced obesity via TLR4/MyD88/MAPK/NF-kB signaling pathways. *Biochem Biophys Res Commun* 2017; 490(2): 349-355.
71. Mesarwi OA, Loomba R, Malhotra A. Obstructive Sleep Apnea, Hypoxia, and Nonalcoholic Fatty Liver Disease. *Am J Respir Crit Care Med* 2019; 199(7): 830-841.
72. Savransky V, Bevans S, Nanayakkara A, Li J, Smith PL, Torbenson MS, Polotsky VY. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. *Am J Physiol Gastrointest Liver Physiol* 2007; 293(4): G871-877.
73. Chen J, Chen J, Fu H, Li Y, Wang L, Luo S, Lu H. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2alpha/PPARalpha pathway. *Am J Physiol Endocrinol Metab* 2019; 317(4): E710-E722.
74. Carrington MJ, Trinder J. Blood pressure and heart rate during continuous experimental sleep fragmentation in healthy adults. *Sleep* 2008; 31(12): 1701-1712.
75. Stamatakis KA, Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal subjects. *Chest* 2010; 137(1): 95-101.
76. Chouchou F, Pichot V, Pepin JL, Tamisier R, Celle S, Maudoux D, Garcin A, Levy P, Barthelemy JC, Roche F, Group PS. Sympathetic overactivity due to sleep fragmentation is associated with elevated diurnal systolic blood pressure in healthy elderly subjects: the PROOF-SYNAPSE study. *Eur Heart J* 2013; 34(28): 2122-2131, 2131a.
77. Bangash MF, Xie A, Skatrud JB, Reichmuth KJ, Barczi SR, Morgan BJ. Cerebrovascular response to arousal from NREM and REM sleep. *Sleep* 2008; 31(3): 321-327.
78. Morgan BJ, Crabtree DC, Puleo DS, Badr MS, Toiber F, Skatrud JB. Neurocirculatory consequences of abrupt change in sleep state in humans. *J Appl Physiol (1985)* 1996; 80(5): 1627-1636.

79. Zhang F, Wu Y, Feng G, Ni X, Xu Z, Gozal D. Polysomnographic correlates of endothelial function in children with obstructive sleep apnea. *Sleep Med* 2018; 52: 45-50.
80. Hirotsu C, Haba-Rubio J, Togeiro SM, Marques-Vidal P, Drager LF, Vollenweider P, Waeber G, Bittencourt L, Tufik S, Heinzer R. Obstructive sleep apnoea as a risk factor for incident metabolic syndrome: a joined Episono and HypnoLaus prospective cohorts study. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2018; 52(5).
81. Kim JS, Azarbarzin A, Wang R, Djonlagic IE, Punjabi NM, Zee PC, Koo BB, Soliman EZ, Younes M, Redline S. Association of novel measures of sleep disturbances with blood pressure: the Multi-Ethnic Study of Atherosclerosis. *Thorax* 2019: [Epub ahead of print].
82. Suzuki M, Shimamoto K, Sekiguchi H, Harada T, Satoya N, Inoue Y, Yamaguchi K, Kawana M. Arousal index as a marker of carotid artery atherosclerosis in patients with obstructive sleep apnea syndrome. *Sleep Breath* 2019; 23(1): 87-94.
83. Bao G, Metreveli N, Fletcher EC. Acute and chronic blood pressure response to recurrent acoustic arousal in rats. *Am J Hypertens* 1999; 12(5): 504-510.
84. Brooks D, Horner RL, Kozar LF, Render-Teixeira CL, Phillipson EA. Obstructive sleep apnea as a cause of systemic hypertension. Evidence from a canine model. *J Clin Invest* 1997; 99(1): 106-109.
85. Launois SH, Averill N, Abraham JH, Kirby DA, Weiss JW. Cardiovascular responses to nonrespiratory and respiratory arousals in a porcine model. *J Appl Physiol (1985)* 2001; 90(1): 114-120.
86. Carreras A, Zhang SX, Peris E, Qiao Z, Gileles-Hillel A, Li RC, Wang Y, Gozal D. Chronic sleep fragmentation induces endothelial dysfunction and structural vascular changes in mice. *Sleep* 2014; 37(11): 1817-1824.
87. McAlpine CS, Kiss MG, Rattik S, He S, Vassalli A, Valet C, Anzai A, Chan CT, Mindur JE, Kahles F, Poller WC, Frodermann V, Fenn AM, Gregory AF, Halle L, Iwamoto Y, Hoyer FF, Binder CJ, Libby P, Tafti M, Scammell TE, Nahrendorf M, Swirski FK. Sleep modulates haematopoiesis and protects against atherosclerosis. *Nature* 2019; 566(7744): 383-387.
88. Gozal D, Khalyfa A, Qiao Z, Akbarpour M, Maccari R, Ottana R. Protein-Tyrosine Phosphatase-1B Mediates Sleep Fragmentation-Induced Insulin Resistance and Visceral Adipose Tissue Inflammation in Mice. *Sleep* 2017; 40(9): zsx111.
89. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. *Sleep* 2010; 33(5): 585-592.
90. Jackson CL, Redline S, Kawachi I, Hu FB. Association between sleep duration and diabetes in black and white adults. *Diabetes Care* 2013; 36(11): 3557-3565.
91. Chandola T, Ferrie JE, Perski A, Akbaraly T, Marmot MG. The effect of short sleep duration on coronary heart disease risk is greatest among those with sleep disturbance: a prospective study from the Whitehall II cohort. *Sleep* 2010; 33(6): 739-744.
92. Tobaldini E, Fiorelli EM, Solbiati M, Costantino G, Nobili L, Montano N. Short sleep duration and cardiometabolic risk: from pathophysiology to clinical evidence. *Nat Rev Cardiol* 2019; 16(4): 213-224.
93. Yin J, Jin X, Shan Z, Li S, Huang H, Li P, Peng X, Peng Z, Yu K, Bao W, Yang W, Chen X, Liu L. Relationship of Sleep Duration With All-Cause Mortality and Cardiovascular Events: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies. *J Am Heart Assoc* 2017; 6(9).

94. Matricciani L, Bin YS, Lallukka T, Kronholm E, Dumuid D, Paquet C, Olds T. Past, present, and future: trends in sleep duration and implications for public health. *Sleep Health* 2017; 3(5): 317-323.
95. Liu Y, Wheaton AG, Chapman DP, Cunningham TJ, Lu H, Croft JB. Prevalence of Healthy Sleep Duration among Adults--United States, 2014. *MMWR Morb Mortal Wkly Rep* 2016; 65(6): 137-141.
96. Rafalson L, Donahue RP, Stranges S, Lamonte MJ, Dmochowski J, Dorn J, Trevisan M. Short sleep duration is associated with the development of impaired fasting glucose: the Western New York Health Study. *Ann Epidemiol* 2010; 20(12): 883-889.
97. Anothaisintawee T, Reutrakul S, Van Cauter E, Thakkinstian A. Sleep disturbances compared to traditional risk factors for diabetes development: Systematic review and meta-analysis. *Sleep Med Rev* 2016; 30: 11-24.
98. Association AD. Standards of Medical Care in Diabetes-2017. *Diabetes Care* 2017; 40(Suppl 1): S1-S142.
99. McDonough RJ, Clements MA, DeLurgio SA, Patton SR. Sleep duration and its impact on adherence in adolescents with type 1 diabetes mellitus. *Pediatr Diabetes* 2017; 18(4): 262-270.
100. Donga E, van Dijk M, van Dijk JG, Biermasz NR, Lammers GJ, van Kralingen KW, Corssmit EP, Romijn JA. A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. *J Clin Endocrinol Metab* 2010; 95(6): 2963-2968.
101. Koren D, Taveras EM. Association of sleep disturbances with obesity, insulin resistance and the metabolic syndrome. *Metabolism* 2018; 84: 67-75.
102. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. *Lancet* 1999; 354(9188): 1435-1439.
103. Al Khatib HK, Hall WL, Creedon A, Ooi E, Masri T, McGowan L, Harding SV, Darzi J, Pot GK. Sleep extension is a feasible lifestyle intervention in free-living adults who are habitually short sleepers: a potential strategy for decreasing intake of free sugars? A randomized controlled pilot study. *Am J Clin Nutr* 2018; 107(1): 43-53.
104. Killick R, Hoyos CM, Melehan KL, Dungan GC, 2nd, Poh J, Liu PY. Metabolic and hormonal effects of 'catch-up' sleep in men with chronic, repetitive, lifestyle-driven sleep restriction. *Clin Endocrinol (Oxf)* 2015; 83(4): 498-507.
105. Leproult R, Deliens G, Gilson M, Peigneux P. Beneficial impact of sleep extension on fasting insulin sensitivity in adults with habitual sleep restriction. *Sleep* 2015; 38(5): 707-715.
106. So-Ngern A, Chirakalwasan N, Saetung S, Chanprasertyothin S, Thakkinstian A, Reutrakul S. Effects of Two-Week Sleep Extension on Glucose Metabolism in Chronically Sleep-Deprived Individuals. *J Clin Sleep Med* 2019; 15(5): 711-718.
107. Tasali E, Chapotot F, Wroblewski K, Schoeller D. The effects of extended bedtimes on sleep duration and food desire in overweight young adults: a home-based intervention. *Appetite* 2014; 80: 220-224.
108. Drager LF, Santos RB, Silva WA, Parise BK, Giatti S, Aiello AN, Souza SP, Furlan SF, Lorenzi-Filho G, Lotufo PA, Bensenor IM. OSA, Short Sleep Duration, and Their Interactions With Sleepiness and Cardiometabolic Risk Factors in Adults: The ELSA-Brasil Study. *Chest* 2019; 155(6): 1190-1198.
109. Risso TT, Poyares D, Rizzi CF, Pulz C, Guilleminault C, Tufik S, de Paola AA, Cintra F. The impact of sleep duration in obstructive sleep apnea patients. *Sleep Breath* 2013; 17(2): 837-843.
110. Matsumoto T, Murase K, Tabara Y, Gozal D, Smith D, Minami T, Tachikawa R, Tanizawa K, Oga T, Nagashima S, Wakamura T, Komenami N, Setoh K, Kawaguchi

- T, Tsutsumi T, Takahashi Y, Nakayama T, Hirai T, Matsuda F, Chin K. Impact of sleep characteristics and obesity on diabetes and hypertension across genders and menopausal status: the Nagahama study. *Sleep* 2018: 41(7): zsy071.
111. Ren R, Covassin N, Yang L, Li Y, Zhang Y, Zhou J, Tan L, Li T, Li X, Wang Y, Zhang J, Wing YK, Li W, Somers VK, Tang X. Objective but Not Subjective Short Sleep Duration Is Associated With Hypertension in Obstructive Sleep Apnea. *Hypertension* 2018: 72(3): 610-617.
 112. Barger LK, Rajaratnam SMW, Cannon CP, Lukas MA, Im K, Goodrich EL, Czeisler CA, O'Donoghue ML. Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome. *J Am Heart Assoc* 2017: 6(10).
 113. He W, Holtkamp S, Hergenhan SM, Kraus K, de Juan A, Weber J, Bradfield P, Grenier JMP, Pelletier J, Druzd D, Chen CS, Ince LM, Bierschenk S, Pick R, Sperandio M, Aurrand-Lions M, Scheiermann C. Circadian Expression of Migratory Factors Establishes Lineage-Specific Signatures that Guide the Homing of Leukocyte Subsets to Tissues. *Immunity* 2018: 49(6): 1175-1190 e1177.
 114. Kurupati RK, Kossenkoff A, Kannan S, Haut LH, Doyle S, Yin X, Schmader KE, Liu Q, Showe L, Ertl HCJ. The effect of timing of influenza vaccination and sample collection on antibody titers and responses in the aged. *Vaccine* 2017: 35(30): 3700-3708.
 115. Pariollaud M, Gibbs JE, Hopwood TW, Brown S, Begley N, Vonslow R, Poolman T, Guo B, Saer B, Jones DH, Tellam JP, Bresciani S, Tomkinson NC, Wojno-Picon J, Cooper AW, Daniels DA, Trump RP, Grant D, Zuercher W, Willson TM, MacDonald AS, Bolognese B, Podolin PL, Sanchez Y, Loudon AS, Ray DW. Circadian clock component REV-ERBalpha controls homeostatic regulation of pulmonary inflammation. *J Clin Invest* 2018: 128(6): 2281-2296.
 116. Gibbs J, Ince L, Matthews L, Mei J, Bell T, Yang N, Saer B, Begley N, Poolman T, Pariollaud M, Farrow S, DeMayo F, Hussell T, Worthen GS, Ray D, Loudon A. An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action. *Nat Med* 2014: 20(8): 919-926.
 117. Pilonis V, Helfrich-Forster C, Oster H. The role of the circadian clock system in physiology. *Pflugers Arch* 2018: 470(2): 227-239.
 118. Durgan DJ, Pulinilkunnil T, Villegas-Montoya C, Garvey ME, Frangogiannis NG, Michael LH, Chow CW, Dyck JR, Young ME. Short communication: ischemia/reperfusion tolerance is time-of-day-dependent: mediation by the cardiomyocyte circadian clock. *Circ Res* 2010: 106(3): 546-550.
 119. Knutsson A, Kempe A. Shift work and diabetes--a systematic review. *Chronobiol Int* 2014: 31(10): 1146-1151.
 120. Morris CJ, Purvis TE, Mistretta J, Scheer FA. Effects of the Internal Circadian System and Circadian Misalignment on Glucose Tolerance in Chronic Shift Workers. *J Clin Endocrinol Metab* 2016: 101(3): 1066-1074.
 121. Vanevski F, Xu B. Molecular and neural bases underlying roles of BDNF in the control of body weight. *Front Neurosci* 2013: 7: 37.
 122. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. *Proc Natl Acad Sci U S A* 2009: 106(11): 4453-4458.
 123. Scheer FA, Hu K, Evoniuk H, Kelly EE, Malhotra A, Hilton MF, Shea SA. Impact of the human circadian system, exercise, and their interaction on cardiovascular function. *Proc Natl Acad Sci U S A* 2010: 107(47): 20541-20546.

124. Borbely AA, Daan S, Wirz-Justice A, Deboer T. The two-process model of sleep regulation: a reappraisal. *J Sleep Res* 2016; 25(2): 131-143.
125. van den Heuvel CJ, Lushington K. Chronobiology and insomnia: pathophysiology and treatment of circadian rhythm sleep disorders. *Expert Rev Neurother* 2002; 2(2): 249-260.
126. Archer SN, Oster H. How sleep and wakefulness influence circadian rhythmicity: effects of insufficient and mistimed sleep on the animal and human transcriptome. *J Sleep Res* 2015; 24(5): 476-493.
127. Cedernaes J, Osler ME, Voisin S, Broman JE, Vogel H, Dickson SL, Zierath JR, Schiøth HB, Benedict C. Acute Sleep Loss Induces Tissue-Specific Epigenetic and Transcriptional Alterations to Circadian Clock Genes in Men. *J Clin Endocrinol Metab* 2015; 100(9): E1255-1261.
128. Cedernaes J, Schonke M, Westholm JO, Mi J, Chibalin A, Voisin S, Osler M, Vogel H, Hornaeus K, Dickson SL, Lind SB, Bergquist J, Schiøth HB, Zierath JR, Benedict C. Acute sleep loss results in tissue-specific alterations in genome-wide DNA methylation state and metabolic fuel utilization in humans. *Sci Adv* 2018; 4(8): eaar8590.
129. Wilms B, Leineweber EM, Molle M, Chamorro R, Pommerenke C, Salinas-Riester G, Sina C, Lehnert H, Oster H, Schmid SM. Sleep Loss Disrupts Morning-to-Evening Differences in Human White Adipose Tissue Transcriptome. *J Clin Endocrinol Metab* 2019; 104(5): 1687-1696.
130. Bagai K, Muldowney JA, 3rd, Song Y, Wang L, Bagai J, Artibee KJ, Vaughan DE, Malow BA. Circadian variability of fibrinolytic markers and endothelial function in patients with obstructive sleep apnea. *Sleep* 2014; 37(2): 359-367.
131. Entzian P, Linnemann K, Schlaak M, Zabel P. Obstructive sleep apnea syndrome and circadian rhythms of hormones and cytokines. *Am J Respir Crit Care Med* 1996; 153(3): 1080-1086.
132. Patel SR, Palmer LJ, Larkin EK, Jenny NS, White DP, Redline S. Relationship between obstructive sleep apnea and diurnal leptin rhythms. *Sleep* 2004; 27(2): 235-239.
133. Phillips C, Hedner J, Berend N, Grunstein R. Diurnal and obstructive sleep apnea influences on arterial stiffness and central blood pressure in men. *Sleep* 2005; 28(5): 604-609.
134. von Kanel R, Natarajan L, Ancoli-Israel S, Mills PJ, Wolfson T, Gamst AC, Loredó JS, Dimsdale JE. Effect of continuous positive airway pressure on day/night rhythm of prothrombotic markers in obstructive sleep apnea. *Sleep Med* 2013; 14(1): 58-65.
135. Barcelo A, Pierola J, de la Pena M, Frontera G, Yanez A, Alonso-Fernandez A, Ayllon O, Agusti AG. Impaired circadian variation of platelet activity in patients with sleep apnea. *Sleep Breath* 2012; 16(2): 355-360.
136. Martinez-Nicolas A, Guaita M, Santamaria J, Montserrat JM, Rol MA, Madrid JA. Circadian Impairment of Distal Skin Temperature Rhythm in Patients With Sleep-Disordered Breathing: The Effect of CPAP. *Sleep* 2017; 40(6).
137. Burioka N, Koyanagi S, Endo M, Takata M, Fukuoka Y, Miyata M, Takeda K, Chikumi H, Ohdo S, Shimizu E. Clock gene dysfunction in patients with obstructive sleep apnoea syndrome. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2008; 32(1): 105-112.
138. Arendt J, Van Someren EJ, Appleton R, Skene DJ, Akerstedt T. Clinical update: melatonin and sleep disorders. *Clin Med (Lond)* 2008; 8(4): 381-383.
139. Hernandez C, Abreu J, Abreu P, Castro A, Jimenez A. Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2007; 30(3): 496-500.

140. Tamisier R, Nieto L, Anand A, Cunnington D, Weiss JW. Sustained muscle sympathetic activity after hypercapnic but not hypocapnic hypoxia in normal humans. *Respir Physiol Neurobiol* 2004; 141(2): 145-155.
141. Ahmadi Z, Bornefalk-Hermansson A, Franklin KA, Midgren B, Ekstrom MP. Hypo- and hypercapnia predict mortality in oxygen-dependent chronic obstructive pulmonary disease: a population-based prospective study. *Respir Res* 2014; 15: 30.
142. Nin N, Muriel A, Penuelas O, Brochard L, Lorente JA, Ferguson ND, Raymondos K, Rios F, Violi DA, Thille AW, Gonzalez M, Villagomez AJ, Hurtado J, Davies AR, Du B, Maggiore SM, Soto L, D'Empaire G, Matamis D, Abroug F, Moreno RP, Soares MA, Arabi Y, Sandi F, Jibaja M, Amin P, Koh Y, Kuiper MA, Bulow HH, Zeggwagh AA, Anzueto A, Sznajder JI, Esteban A, Group V. Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome. *Intensive Care Med* 2017; 43(2): 200-208.
143. O'Croinin DF, Nichol AD, Hopkins N, Boylan J, O'Brien S, O'Connor C, Laffey JG, McLoughlin P. Sustained hypercapnic acidosis during pulmonary infection increases bacterial load and worsens lung injury. *Crit Care Med* 2008; 36(7): 2128-2135.
144. Acute Respiratory Distress Syndrome N, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000; 342(18): 1301-1308.
145. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, Kairalla RA, Deheinzelin D, Munoz C, Oliveira R, Takagaki TY, Carvalho CR. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. *N Engl J Med* 1998; 338(6): 347-354.
146. Horie S, Ansari B, Masterson C, Devaney J, Scully M, O'Toole D, Laffey JG. Hypercapnic acidosis attenuates pulmonary epithelial stretch-induced injury via inhibition of the canonical NF-kappaB pathway. *Intensive Care Med Exp* 2016; 4(1): 8.
147. Laffey JG, Honan D, Hopkins N, Hyvelin JM, Boylan JF, McLoughlin P. Hypercapnic acidosis attenuates endotoxin-induced acute lung injury. *Am J Respir Crit Care Med* 2004; 169(1): 46-56.
148. Casalino-Matsuda SM, Wang N, Ruhoff PT, Matsuda H, Nlend MC, Nair A, Szleifer I, Beitel GJ, Sznajder JI, Sporn PHS. Hypercapnia Alters Expression of Immune Response, Nucleosome Assembly and Lipid Metabolism Genes in Differentiated Human Bronchial Epithelial Cells. *Sci Rep* 2018; 8(1): 13508.
149. Oliver KM, Lenihan CR, Bruning U, Cheong A, Laffey JG, McLoughlin P, Taylor CT, Cummins EP. Hypercapnia induces cleavage and nuclear localization of RelB protein, giving insight into CO₂ sensing and signaling. *J Biol Chem* 2012; 287(17): 14004-14011.
150. Shigemura M, Lecuona E, Angulo M, Homma T, Rodriguez DA, Gonzalez-Gonzalez FJ, Welch LC, Amarelle L, Kim SJ, Kaminski N, Budinger GRS, Solway J, Sznajder JI. Hypercapnia increases airway smooth muscle contractility via caspase-7-mediated miR-133a-RhoA signaling. *Sci Transl Med* 2018; 10(457).
151. Jaitovich A, Angulo M, Lecuona E, Dada LA, Welch LC, Cheng Y, Gusarova G, Ceco E, Liu C, Shigemura M, Barreiro E, Patterson C, Nader GA, Sznajder JI. High CO₂ levels cause skeletal muscle atrophy via AMP-activated kinase (AMPK), FoxO3a protein, and muscle-specific Ring finger protein 1 (MuRF1). *J Biol Chem* 2015; 290(14): 9183-9194.
152. Wang N, Gates KL, Trejo H, Favoreto S, Jr., Schleimer RP, Sznajder JI, Beitel GJ, Sporn PH. Elevated CO₂ selectively inhibits interleukin-6 and tumor necrosis factor

- expression and decreases phagocytosis in the macrophage. *FASEB J* 2010; 24(7): 2178-2190.
153. Cummins EP, Oliver KM, Lenihan CR, Fitzpatrick SF, Bruning U, Scholz CC, Slattery C, Leonard MO, McLoughlin P, Taylor CT. NF-kappaB links CO2 sensing to innate immunity and inflammation in mammalian cells. *J Immunol* 2010; 185(7): 4439-4445.
 154. Keogh CE, Scholz CC, Rodriguez J, Selfridge AC, von Kriegsheim A, Cummins EP. Carbon dioxide-dependent regulation of NF-kappaB family members RelB and p100 gives molecular insight into CO2-dependent immune regulation. *J Biol Chem* 2017; 292(27): 11561-11571.
 155. Linz D, Schotten U, Neuberger HR, Bohm M, Wirth K. Negative tracheal pressure during obstructive respiratory events promotes atrial fibrillation by vagal activation. *Heart Rhythm* 2011; 8(9): 1436-1443.
 156. Orban M, Bruce CJ, Pressman GS, Leinveber P, Romero-Corral A, Korinek J, Konecny T, Villarraga HR, Kara T, Caples SM, Somers VK. Dynamic changes of left ventricular performance and left atrial volume induced by the mueller maneuver in healthy young adults and implications for obstructive sleep apnea, atrial fibrillation, and heart failure. *Am J Cardiol* 2008; 102(11): 1557-1561.
 157. Schlatzer C, Schwarz EI, Sievi NA, Clarenbach CF, Gaisl T, Haegeli LM, Duru F, Stradling JR, Kohler M. Intrathoracic pressure swings induced by simulated obstructive sleep apnoea promote arrhythmias in paroxysmal atrial fibrillation. *Europace* 2016; 18(1): 64-70.
 158. Durgan DJ, Ganesh BP, Cope JL, Ajami NJ, Phillips SC, Petrosino JF, Hollister EB, Bryan RM, Jr. Role of the Gut Microbiome in Obstructive Sleep Apnea-Induced Hypertension. *Hypertension* 2016; 67(2): 469-474.
 159. Farre N, Farre R, Gozal D. Sleep Apnea Morbidity: A Consequence of Microbial-Immune Cross-Talk? *Chest* 2018; 154(4): 754-759.
 160. Bailly S, Destors M, Grillet Y, Richard P, Stach B, Vivodtzev I, Timsit JF, Levy P, Tamisier R, Pepin JL, scientific c, investigators of the French national sleep apnea r. Obstructive Sleep Apnea: A Cluster Analysis at Time of Diagnosis. *PLoS One* 2016; 11(6): e0157318.
 161. Keenan BT, Kim J, Singh B, Bittencourt L, Chen NH, Cistulli PA, Magalang UJ, McArdle N, Mindel JW, Benediktsdottir B, Arnardottir ES, Prochnow LK, Penzel T, Sanner B, Schwab RJ, Shin C, Sutherland K, Tufik S, Maislin G, Gislason T, Pack AI. Recognizable clinical subtypes of obstructive sleep apnea across international sleep centers: a cluster analysis. *Sleep* 2018; 41(3).
 162. Mazzotti DR, Keenan BT, Lim DC, Gottlieb DJ, Kim J, Pack AI. Symptom Subtypes of Obstructive Sleep Apnea Predict Incidence of Cardiovascular Outcomes. *Am J Respir Crit Care Med* 2019; 200(4): 493-506.
 163. Saaresranta T, Hedner J, Bonsignore MR, Riha RL, McNicholas WT, Penzel T, Anttalainen U, Kvamme JA, Pretl M, Sliwinski P, Verbraecken J, Grote L, Group ES. Clinical Phenotypes and Comorbidity in European Sleep Apnoea Patients. *PLoS One* 2016; 11(10): e0163439.
 164. Martinez-Garcia MA, Campos-Rodriguez F, Javaheri S, Gozal D. Pro: continuous positive airway pressure and cardiovascular prevention. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2018; 51(5).
 165. McEvoy RD, Kohler M. Con: continuous positive airway pressure and cardiovascular prevention. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2018; 51(5).

166. Ryan S. Pro: should asymptomatic patients with moderate-to-severe OSA be treated? *Breathe (Sheff)* 2019; 15(1): 7-10.
167. Vakulin A, Chai-Coetzer CL, McEvoy RD. Con: should asymptomatic patients with moderate-to-severe OSA be treated? *Breathe (Sheff)* 2019; 15(1): 11-14.
168. Kohler M, Craig S, Pepperell JCT, Nicoll D, Bratton DJ, Nunn AJ, Leeson P, Stradling JR. CPAP improves endothelial function in patients with minimally symptomatic OSA: results from a subset study of the MOSAIC trial. *Chest* 2013; 144(3): 896-902.
169. Schwarz EI, Puhan MA, Schlatzer C, Stradling JR, Kohler M. Effect of CPAP therapy on endothelial function in obstructive sleep apnoea: A systematic review and meta-analysis. *Respirology* 2015; 20(6): 889-895.
170. Schein AS, Kerkhoff AC, Coronel CC, Plentz RD, Sbruzzi G. Continuous positive airway pressure reduces blood pressure in patients with obstructive sleep apnea; a systematic review and meta-analysis with 1000 patients. *J Hypertens* 2014; 32(9): 1762-1773.
171. Iftikhar IH, Hoyos CM, Phillips CL, Magalang UJ. Meta-analyses of the Association of Sleep Apnea with Insulin Resistance, and the Effects of CPAP on HOMA-IR, Adiponectin, and Visceral Adipose Fat. *J Clin Sleep Med* 2015; 11(4): 475-485.
172. Yang D, Liu Z, Yang H. The impact of effective continuous positive airway pressure on homeostasis model assessment insulin resistance in non-diabetic patients with moderate to severe obstructive sleep apnea. *Diabetes Metab Res Rev* 2012; 28(6): 499-504.
173. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R, Drager LF, Liu Z, Chen G, Du B, McArdle N, Mukherjee S, Tripathi M, Billot L, Li Q, Lorenzi-Filho G, Barbe F, Redline S, Wang J, Arima H, Neal B, White DP, Grunstein RR, Zhong N, Anderson CS, Investigators S, Coordinators. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. *N Engl J Med* 2016; 375(10): 919-931.
174. Peker Y, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunstrom E. Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial. *Am J Respir Crit Care Med* 2016; 194(5): 613-620.
175. Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of Adult Obstructive Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and GRADE Assessment. *J Clin Sleep Med* 2019; 15(2): 301-334.
176. Yu J, Zhou Z, McEvoy RD, Anderson CS, Rodgers A, Perkovic V, Neal B. Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis. *JAMA* 2017; 318(2): 156-166.
177. Sanchez-de-la-Torre M, Sanchez-de-la-Torre A, Bertran S, Abad J, Duran-Cantolla J, Cabriada V, Mediano O, Masdeu MJ, Alonso ML, Masa JF, Barcelo A, de la Pena M, Mayos M, Coloma R, Montserrat JM, Chiner E, Perello S, Rubinos G, Minguez O, Pascual L, Cortijo A, Martinez D, Aldoma A, Dalmases M, McEvoy RD, Barbe F, Spanish Sleep N. Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial. *Lancet Respir Med* 2019.
178. Barbe F, Duran-Cantolla J, Sanchez-de-la-Torre M, Martinez-Alonso M, Carmona C, Barcelo A, Chiner E, Masa JF, Gonzalez M, Marin JM, Garcia-Rio F, Diaz de Atauri J, Teran J, Mayos M, de la Pena M, Monasterio C, del Campo F, Montserrat JM, Spanish S, Breathing N. Effect of continuous positive airway pressure on the incidence of

- hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. *JAMA* 2012; 307(20): 2161-2168.
179. Castro-Grattoni AL, Torres G, Martinez-Alonso M, Barbe F, Turino C, Sanchez-de-la-Torre A, Cortijo A, Duran-Cantolla J, Egea C, Cao G, Sanchez-de-la-Torre M. Blood pressure response to CPAP treatment in subjects with obstructive sleep apnoea: the predictive value of 24-h ambulatory blood pressure monitoring. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2017; 50(4).
 180. Martinez-Garcia MA, Capote F, Campos-Rodriguez F, Lloberes P, Diaz de Atauri MJ, Somoza M, Masa JF, Gonzalez M, Sacristan L, Barbe F, Duran-Cantolla J, Aizpuru F, Manas E, Barreiro B, Mosteiro M, Cebrian JJ, de la Pena M, Garcia-Rio F, Maimo A, Zapater J, Hernandez C, Grau SanMarti N, Montserrat JM, Spanish Sleep N. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. *JAMA* 2013; 310(22): 2407-2415.
 181. Quan W, Zheng D, Douglas McEvoy R, Barbe F, Chen R, Liu Z, Loffler K, Lorenzi-Filho G, Luo Y, Mukherjee S, Tripathi M, Woodman R, Li Q, Wang X, Arima H, Xiao Y, Zhang X, Anderson CS, Investigators S. High Risk Characteristics for Recurrent Cardiovascular Events among Patients with Obstructive Sleep Apnoea in the SAVE Study. *EClinicalMedicine* 2018; 2-3: 59-65.
 182. Sanchez-de-la-Torre M, Khalyfa A, Sanchez-de-la-Torre A, Martinez-Alonso M, Martinez-Garcia MA, Barcelo A, Lloberes P, Campos-Rodriguez F, Capote F, Diaz-de-Atauri MJ, Somoza M, Gonzalez M, Masa JF, Gozal D, Barbe F, Spanish Sleep N. Precision Medicine in Patients With Resistant Hypertension and Obstructive Sleep Apnea: Blood Pressure Response to Continuous Positive Airway Pressure Treatment. *J Am Coll Cardiol* 2015; 66(9): 1023-1032.
 183. Bratton DJ, Gaisl T, Wons AM, Kohler M. CPAP vs Mandibular Advancement Devices and Blood Pressure in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis. *JAMA* 2015; 314(21): 2280-2293.
 184. Hudgel DW, Patel SR, Ahasic AM, Bartlett SJ, Bessesen DH, Coaker MA, Fiander PM, Grunstein RR, Gurubhagavatula I, Kapur VK, Lettieri CJ, Naughton MT, Owens RL, Pepin JL, Tuomilehto H, Wilson KC, American Thoracic Society Assembly on S, Respiratory N. The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea. An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med* 2018; 198(6): e70-e87.
 185. Chirinos JA, Gurubhagavatula I, Teff K, Rader DJ, Wadden TA, Townsend R, Foster GD, Maislin G, Saif H, Broderick P, Chittams J, Hanlon AL, Pack AI. CPAP, weight loss, or both for obstructive sleep apnea. *N Engl J Med* 2014; 370(24): 2265-2275.
 186. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP, Obesity S, Prediabetes NNSG. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. *N Engl J Med* 2015; 373(1): 11-22.
 187. Johns DJ, Hartmann-Boyce J, Jebb SA, Aveyard P, Behavioural Weight Management Review G. Diet or exercise interventions vs combined behavioral weight management programs: a systematic review and meta-analysis of direct comparisons. *J Acad Nutr Diet* 2014; 114(10): 1557-1568.
 188. Kelley GA, Kelley KA, Tran ZV. Aerobic exercise and resting blood pressure: a meta-analytic review of randomized, controlled trials. *Prev Cardiol* 2001; 4(2): 73-80.

189. Pepin JL, Tamisier R, Barone-Rochette G, Launois SH, Levy P, Baguet JP. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. *Am J Respir Crit Care Med* 2010; 182(7): 954-960.
190. Chapman JL, Vakulin A, Hedner J, Yee BJ, Marshall NS. Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2016; 47(5): 1420-1428.
191. Dauvilliers Y, Verbraecken J, Partinen M, Hedner J, Saaresranta T, Georgiev O, Tiholov R, Lecomte I, Tamisier R, Levy P, Scart-Gres C, Lecomte JM, Schwartz JC, Pepin JL, group HIs. Pitolisant for Daytime Sleepiness in Obstructive Sleep Apnea Patients Refusing CPAP: A Randomized Trial. *Am J Respir Crit Care Med* 2020.
192. Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP, Investigators TS. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. *Am J Respir Crit Care Med* 2019; 199(11): 1421-1431.
193. Martinez-Garcia MA, Campos-Rodriguez F, Barbe F, Gozal D, Agusti A. Precision medicine in obstructive sleep apnoea. *Lancet Respir Med* 2019; 7(5): 456-464.
194. Budhiraja R, Thomas R, Kim M, Redline S. The Role of Big Data in the Management of Sleep-Disordered Breathing. *Sleep Med Clin* 2016; 11(2): 241-255.
195. Gill J, Prasad V. Improving observational studies in the era of big data. *Lancet* 2018; 392(10149): 716-717.
196. Pepin JL, Jullian-Desayes I, Sapene M, Treptow E, Joyeux-Faure M, Benmerad M, Bailly S, Grillet Y, Stach B, Richard P, Levy P, Muir JF, Tamisier R. Multimodal Remote Monitoring of High Cardiovascular Risk Patients With OSA Initiating CPAP: A Randomized Trial. *Chest* 2019; 155(4): 730-739.
197. Drager LF, McEvoy RD, Barbe F, Lorenzi-Filho G, Redline S, Initiative I. Sleep Apnea and Cardiovascular Disease: Lessons From Recent Trials and Need for Team Science. *Circulation* 2017; 136(19): 1840-1850.
198. Relton C, Torgerson D, O'Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design. *BMJ* 2010; 340: c1066.
199. Carrigan G, Whipple S, Capra WB, Taylor MD, Brown JS, Lu M, Arnieri B, Copping R, Rothman KJ. Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof-of-Concept in Randomized Controlled Trials. *Clin Pharmacol Ther* 2020; 107(2): 369-377.
200. Rajkomar A, Dean J, Kohane I. Machine Learning in Medicine. Reply. *N Engl J Med* 2019; 380(26): 2589-2590.
201. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med* 2019; 25(1): 44-56.
202. Pepin JL, Letesson C, Le-Dong NN, Dedave A, Denison S, Cuthbert V, Martinot JB, Gozal D. Assessment of Mandibular Movement Monitoring With Machine Learning Analysis for the Diagnosis of Obstructive Sleep Apnea. *JAMA Netw Open* 2020; 3(1): e1919657.
203. Stephansen JB, Olesen AN, Olsen M, Ambati A, Leary EB, Moore HE, Carrillo O, Lin L, Han F, Yan H, Sun YL, Dauvilliers Y, Scholz S, Barateau L, Hogg B, Stefani A, Hong SC, Kim TW, Pizza F, Plazzi G, Vandi S, Antelmi E, Perrin D, Kuna ST, Schweitzer PK, Kushida C, Peppard PE, Sorensen HBD, Jennum P, Mignot E. Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy. *Nat Commun* 2018; 9(1): 5229.

204. Linz D, Brooks AG, Elliott AD, Nalliah CJ, Hendriks JML, Middeldorp ME, Gallagher C, Mahajan R, Kalman JM, McEvoy RD, Lau DH, Sanders P. Variability of Sleep Apnea Severity and Risk of Atrial Fibrillation: The VARIOS-AF Study. *JACC Clin Electrophysiol* 2019; 5(6): 692-701.
205. Arnaud C, Bouyon S, Recoquillon S, Brasseur S, Lemarie E, Briancon-Marjollet A, Gonthier B, Toral M, Faury G, Martinez MC, Andriantsitohaina R, Pepin JL. Nonmuscle Myosin Light Chain Kinase: A Key Player in Intermittent Hypoxia-Induced Vascular Alterations. *J Am Heart Assoc* 2018; 7(3).
206. Cortese R, Gileles-Hillel A, Khalyfa A, Almendros I, Akbarpour M, Khalyfa AA, Qiao Z, Garcia T, Andrade J, Gozal D. Aorta macrophage inflammatory and epigenetic changes in a murine model of obstructive sleep apnea: Potential role of CD36. *Sci Rep* 2017; 7: 43648.
207. Farre N, Otero J, Falcones B, Torres M, Jorba I, Gozal D, Almendros I, Farre R, Navajas D. Intermittent Hypoxia Mimicking Sleep Apnea Increases Passive Stiffness of Myocardial Extracellular Matrix. A Multiscale Study. *Front Physiol* 2018; 9: 1143.
208. Rubies C, Dantas AP, Batlle M, Torres M, Farre R, Sanguesa G, Montserrat JM, Mont L, Almendros I, Guasch E. Aortic remodelling induced by obstructive apneas is normalized with mesenchymal stem cells infusion. *Sci Rep* 2019; 9(1): 11443.
209. Suarez-Giron MC, Castro-Grattoni A, Torres M, Farre R, Barbe F, Sanchez-de-la-Torre M, Gozal D, Picado C, Montserrat JM, Almendros I. Acetylsalicylic Acid Prevents Intermittent Hypoxia-Induced Vascular Remodeling in a Murine Model of Sleep Apnea. *Front Physiol* 2018; 9: 600.
210. Conotte S, Tassin A, Conotte R, Colet JM, Zouaoui Boudjeltia K, Legrand A. Metabonomic profiling of chronic intermittent hypoxia in a mouse model. *Respir Physiol Neurobiol* 2018; 256: 157-173.
211. Khalyfa A, Gozal D, Masa JF, Marin JM, Qiao Z, Corral J, Gonzalez M, Marti S, Kheirandish-Gozal L, Egea C, Sanchez-Quiroga MA, de Terreros FJG, Barca FJ. Sleep-disordered breathing, circulating exosomes, and insulin sensitivity in adipocytes. *Int J Obes (Lond)* 2018; 42(6): 1127-1139.
212. Thomas A, Belaidi E, Moulin S, Horman S, van der Zon GC, Viollet B, Levy P, Bertrand L, Pepin JL, Godin-Ribuot D, Guigas B. Chronic Intermittent Hypoxia Impairs Insulin Sensitivity but Improves Whole-Body Glucose Tolerance by Activating Skeletal Muscle AMPK. *Diabetes* 2017; 66(12): 2942-2951.

Table 1: Important contributions from experimental studies investigating the effects of IH on cardiovascular and metabolic outcomes published within the last 3 years


	Study	Characteristics of IH	Species, Cells	Main message
CARDIOVASCULAR DISEASE	Arnaud C et al. 2018 [205]	21-5 % O ₂ , 60 events/h, 8 h/day, 14 days	12 wks-old wildtype and nmMLCK ^{-/-} mice	Non-muscle myosin light chain kinase is a key mechanism in IH-induced vascular oxidative stress, inflammation and barrier dysfunction
	Badran M et al. 2019 [59]	21–12% O ₂ , 60 events/h, 12 h/day, 18 days	8 wks-old mice	Gestational intermittent hypoxia promotes vascular disease in adult male offsprings
	Castro-Grattoni AL et al. 2016 [57]	20-6 % O ₂ , 60 events/h, 6 h/day, 6 wks and 6 wks recovery	6 wks-old mice	IH-induced cardiovascular injury can be reversed by normoxia
	Cortese R et al. 2017 [206]	21-6 % O ₂ , 20 events/h, 12 h/day, 20 wks	22–25 g C57Bl/6 WT and CD36 ^{-/-} mice	IH promotes the recruitment of metabolic active macrophages to the aortic wall triggering atherogenesis and this was absent in CD36 ^{-/-} mice
	Farre N et al. 2018 [207]	20-6 % O ₂ , 60 events/h, 6 h/day, 8 wks	2 and 18 months-old mice	IH increases passive stiffness of myocardial extracellular matrix
	Rubies C et al. 2019 [208]	15 s upper airway obstructions (60/h, 6 h/day, 21 days.	250–300 g Sprague-Dawley rats	Mesenchymal stem cell infusion blunts OSA-related vascular changes
	Sharma P et al. 2018 [55]	30 min 1% O ₂ , 30 min 21% O ₂ , 9 cycles	Human coronary artery endothelial cells	IH upregulates caveolin-1 and endothelin-1 expression
	Song D et al. 2018 [56]	20-6 % O ₂ , 60 events/h, 8 h/day, 9 wks	ApoE ^{-/-} and ApoE ^{-/-} overexpressing an IκB mutant mice	IH activates NFκB-pathway in aorta with progression of atherosclerosis with significant attenuation in mutant mice
	Suarez-Giron MC et al. 2018 [209]	20-6 % O ₂ , 60 events/h, 6 h/day, 8 wks	6 wks-old C57Bl/6J mice	Acetylsalicylic acid prevents IH-Induced vascular remodeling
	Takahashi K et al. 2018 [52]	21-10 % O ₂ , 12 events/h, 8 h/day, 4 wks	8 wks-old male C57Bl/6J mice	IH-induced renal sympathetic nerve activation is involved in systemic oxidative stress, endothelial dysfunction, and renin-angiotensin activation
METABOLIC ALTERATIONS	Conotte S et al. 2018 [210]	21-6 % O ₂ , 60 events/h, 8 h/day, 35 days	9 wks-old mice	Alteration in energy metabolism towards anaerobic pathways. Excess production of vitamin B3, liver function modulations and a stimulation of creatine synthesis
	Gozal D et al. 2017 [65]	21-6 % O ₂ , 20 events/h, 12 h/day, 6 wks vs continuous 8% O ₂ (SH)	8 wks-old C57Bl/6J mice	In contrast to SH, IH induces whitening and inflammation of adipose tissue with insulin resistance
	Khalyfa et al. 2018 [211]	21-6 % O ₂ , 20 events/h, 12 h/day, 2-20 wks	22–25 g mice	Alterations in exosomal cargo in response to IH impede on insulin-signalling pathway in cultured adipocytes
	Murphy AM et al 2017 [24]	Mice: 21-5 % O ₂ , 60 events/h, 8 h/day, 6 wks Cells: 40s 16% O ₂ , 40s 3% O ₂ , 8 hrs/d, 3 d	19 wks C57Bl/6J mice fed on low or high-fat diet 3T3-L1 murine adipocytes THP-1-derived macrophages	IH induces a pro-inflammatory phenotype of adipose tissue with polarization of macrophages towards an M1-phenotype contributing to the pathogenesis of IH-mediated insulin resistance
	Polak J et al 2018 [66]	21-6 % O ₂ , 60 events/h, 12 h/day, 2 weeks	6-8 wks old male C57Bl/6J mice	IH led to impaired glucose tolerance and insulin resistance and these responses were partially ameliorated with pharmacological blockage of Endothelin-1 type B receptor
	Poulain L et al. 2017 [62]	21-5% O ₂ , 60 s cycle, 8 h/day, 6 wks	8 wks-old C57Bl/6J mice	IH reduces epididymal adipose tissue but induces glucose dysregulation. Thus, IH-induced inflammatory remodeling could represent the main determinant of metabolic dysfunction
	Thomas A et al. 2017 [212]	21-5 % O ₂ , 60 events/h, 8 h/day, 5 days	8 wks-old wildtype, AMPKα2 ^{-/-} , muscle-specific AMPKα1α2 ^{-/-} mice	IH impairs insulin sensitivity but improves glucose tolerance by activating skeletal muscle AMPK

Figure Legends

Figure 1: Protective and detrimental effects of intermittent hypoxia depending on the characteristics of the pattern of obstructive sleep apnoea and other modifying factors.

Figure 2: Schematic depiction of the normal mammalian circadian clock. *Environmental cues such as light/dark cycle, mealtimes or physical activity influence the central and peripheral clocks. The central clock, located in the suprachiasmatic nucleus (SCN) of the hypothalamus, synchronizes and entrains peripheral circadian clocks via neural and endocrine pathways. The resulting oscillations of clock proteins and activity translates into circadian behaviour and physiology, i.e. sleep/wakefulness, upper airway collapsibility, metabolic rhythms or immune responses.*

Figure 3: Pathophysiological traits for cardiovascular and metabolic diseases in obstructive sleep apnoea (OSA).



Environmental Cues



Light/Darkness




Feeding
schedules





Physical
Activity




Hormonal and Neural Signals



**Peripheral
Clocks**





**Understanding the Pathophysiological Mechanisms of Cardiometabolic
Complications in Obstructive Sleep Apnoea – Towards Personalized
Treatment Approaches**

ONLINE DATA SUPPLEMENT

Silke Ryan, Eoin P Cummins, Ramon Farre, Alex Gileles-Hillel, Jonathan C Jun, Henrik Oster, Jean-Louis Pepin, David W Ray, Sirimon Reutrakul, Manuel Sanchez-de-la-Torre, Renaud Tamisier and Isaac Almendros

List of participants of the Research Seminar

Name	Country	Role
Silke Ryan	Ireland	Seminar's organiser & Session Chair
Isaac Almendros	Spain	Seminar's Co-organiser & Speaker & Session Chair
Mary Morrell	United Kingdom	Speaker
Sirimon Reutrakul	USA	Speaker & Session Chair
Henrik Oster	Germany	Speaker
Alexander Gileles-Hillel	Israel	Speaker
Ramon Farre	Spain	Speaker & Session Chair
Renaud Tamisier	France	Speaker & Session Chair
Jonathan Jun	USA	Speaker & Session Chair
Eoin Cummins	Ireland	Speaker
David Ray	United Kingdom	Speaker
Jean-Louis Pepin	France	Speaker & Session Chair
Manuel Sanchez de la Torre	Spain	Speaker
Walter McNicholas	Ireland	Session Chair
Iana Andreieva	Ukraine	Participant
Claire Arnaud	France	Participant
Elise Belaidi	France	Participant
Andras Bikov	United Kingdom	Participant
Maria Bonsignore	Italy	Participant
Candelaria Caballero Eraso	Spain	Participant
Alexopoulou Christina	Greece	Participant
Nuno Coelho	Portugal	Participant
Maria Correia	Portugal	Participant
Jonathan Gaucher	France	Participant
Angela Gomez-Niño	Spain	Participant
Nils Henrik Holmedahl	Norway	Participant
Bonovolias Ioannis	Greece	Participant
Emília Monteiro	Portugal	Participant
Campillo Noelia	Spain	Participant
Athanasia Pataka	Greece	Participant
Fotis Perlikos	Greece	Participant
Martin Petrek	Czech Republic	Participant
Joana Sacramento	Portugal	Participant
Esther Irene Schwarz	Switzerland	Participant
Paschalis Steiropoulos	Greece	Participant
Dries Testelmans	Belgium	Participant
Masako Ueyama	Japan	Participant
Silvia V. Conde	Portugal	Participant
Guoda Vaitukaitiene	Lithuania	Participant
Theodoros Vassilakopoulos	Greece	Participant
Guillaume Vial	France	Participant
Ding Zou	Sweden	Participant
Shannon Cox	Ireland	Participant

Annie Curtis	Ireland	Participant
Lauren Fagan	Ireland	Participant
Susan Fitzpatrick	Ireland	Participant
James O'Siorain	Ireland	Participant
Frederic Nicolas	United Kingdom	Participant
Carlos Teixeira	Portugal	Participant
Tom Kelly	United Kingdom	Participant